<SEC-DOCUMENT>0000950123-11-026605.txt : 20110318
<SEC-HEADER>0000950123-11-026605.hdr.sgml : 20110318
<ACCEPTANCE-DATETIME>20110318060717
ACCESSION NUMBER:		0000950123-11-026605
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20110318
DATE AS OF CHANGE:		20110318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-171615
		FILM NUMBER:		11696734

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>y04358bbe424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
<TITLE>e424b5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Filed
    Pursuant to Rule&#160;424(b)(5)</FONT></B>
</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Registration
    <FONT style="white-space: nowrap">No.&#160;333-171615</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>PROSPECTUS SUPPLEMENT</B>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>(To Prospectus Dated January&#160;13, 2011)</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 18pt">4,000,000&#160;Shares</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04358bbe0435801.gif" alt="(PROTALIX LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 18pt">Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are selling 4,000,000&#160;shares of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock is listed on the NYSE Amex under the symbol
    &#147;PLX&#148; and on the Tel Aviv Stock Exchange under the
    trading symbol &#147;PLX.&#148; On March&#160;17, 2011, the last
    reported sale price of our common stock was $6.10 per share on
    the NYSE Amex and NIS 22.15 per share on the Tel Aviv Stock
    Exchange.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 5%; font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Investing in our common stock involves risks. See &#147;Risk
    Factors&#148; beginning on
    <FONT style="white-space: nowrap">page&#160;S-6</FONT>
    of this prospectus supplement.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Neither the Securities and Exchange Commission, the Israeli
    Securities Authority nor any state securities commission has
    approved or disapproved of these securities or determined if
    prospectus supplement or the accompanying prospectus is truthful
    or complete. Any representation to the contrary is a criminal
    offense.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="79%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Public Offering Price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    22,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Underwriting Discount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,320,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeds to Protalix BioTherapeutics (before expenses)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20,680,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The underwriters expect to deliver the shares to purchasers on
    or about March&#160;23, 2011 through the book-entry facilities
    of The Depository Trust&#160;Company.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Joint Book-Running Managers</I></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="50%"></TD>
    <TD width="50%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <B><FONT style="font-size: 24pt; font-family: 'Times New Roman', Times">Citi</FONT></B></TD>
    <TD nowrap align="right">    <B><FONT style="font-size: 24pt; font-family: 'Times New Roman', Times">
    Barclays Capital</FONT></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    March&#160;17, 2011
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>You should rely only on the information contained in or
    incorporated by reference in this prospectus supplement and the
    accompanying prospectus. We have not authorized anyone to
    provide you with different information. If anyone provides you
    with different or inconsistent information, you should not rely
    on it. We are not, and the underwriters are not, making an offer
    to sell these securities in any state or jurisdiction where the
    offer or sale is not permitted. You should not assume that the
    information contained in this prospectus supplement or the
    accompanying prospectus is accurate as of any date other than
    the date on the front of this prospectus supplement or the
    accompanying prospectus. Persons outside the United States who
    come into possession of this prospectus supplement must inform
    themselves about, and observe, any restrictions relating to the
    offering of the common stock and the distribution of this
    prospectus supplement outside the United States</B>.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Prospectus
    Supplement</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="E04358tocpage"></A>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="97%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358114'>About This Prospectus Supplement</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-ii
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358115'>Prospectus Supplement Summary</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358116'>The Offering</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358117'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-6
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358118'>Cautionary Statement Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358119'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-12
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358120'>Price Range of Common Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-13
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358121'>Capitalization</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-15
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358128'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-16
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358122'>Certain U.S. Federal Income and Estate Tax
    Consequences to
    <FONT style="white-space: nowrap">Non-U.S.</FONT>
    Holders of Common Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-17
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358123'>Underwriting</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-20
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358124'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-25
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358125'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-25
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358126'>Where You Can Find More Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-25
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#E04358127'>Incorporation of Certain Documents by
    Reference</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    S-26
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Prospectus</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="97%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cautionary Statement Regarding Forward-Looking Statements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    About This Prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Business
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk Factors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Use of Proceeds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dilution
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Securities We May Offer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Description of Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Plan of Distribution
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Where You Can Find More Information
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Incorporation of Certain Documents by Reference
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal Matters
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Experts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358114'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus supplement is a supplement to the accompanying
    prospectus dated January&#160;13, 2011 that is also a part of
    this document. This prospectus supplement and the accompanying
    prospectus are part of a registration statement that we filed
    with the Securities and Exchange Commission, or the SEC, using a
    &#147;shelf&#148; registration process. Under the shelf
    registration process, from time to time, we may sell any of the
    securities described in the accompanying prospectus in one or
    more offerings. In this prospectus supplement, we provide you
    with specific information about this offering. This prospectus
    supplement, the accompanying prospectus and the documents
    incorporated by reference herein and therein include important
    information about us, our common stock and other information you
    should know before investing in our common stock. This
    prospectus supplement also adds, updates and changes information
    contained in the accompanying prospectus. To the extent that any
    statement that we make in this prospectus supplement is
    inconsistent with the statements made in the accompanying
    prospectus or in any document incorporated by reference that was
    filed with the SEC before the date of this prospectus
    supplement, the statements made in the accompanying prospectus,
    or such an earlier filing, as applicable, are deemed modified or
    superseded by the statements made in this prospectus supplement.
    You should read both this prospectus supplement and the
    accompanying prospectus as well as the additional information
    described in this prospectus supplement under the headings
    &#147;Where You Can Find More Information&#148; on
    <FONT style="white-space: nowrap">page&#160;S-25</FONT>
    and &#147;Incorporation of Certain Documents by Reference&#148;
    on
    <FONT style="white-space: nowrap">page&#160;S-26</FONT>
    before investing in our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of this prospectus supplement and the accompanying
    prospectus, references to the terms &#147;Protalix,&#148;
    we,&#148; &#147;us&#148; and &#147;our&#148; refer to Protalix
    BioTherapeutics, Inc. and its consolidated subsidiaries, unless
    the context otherwise requires.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All references in this prospectus supplement to &#147;$,&#148;
    &#147;U.S.&#160;Dollars&#148; and &#147;dollars&#148; are to
    United States dollars.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus supplement, the accompanying prospectus and the
    information incorporated by reference herein and therein include
    trademarks, service marks and trade names owned by us or other
    companies. All trademarks, service marks and trade names
    included or incorporated by reference into this prospectus
    supplement or the accompanying prospectus are the property of
    their respective owners.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-ii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<A name='E04358115'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    SUPPLEMENT SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>The following summary highlights certain information
    contained elsewhere in this prospectus supplement, the
    accompanying prospectus, any free writing prospectus that we
    have authorized to use and the documents incorporated by
    reference herein and in the accompanying prospectus. This
    summary does not contain all the information you will need in
    making your investment decision. You should carefully read this
    entire prospectus supplement, the accompanying prospectus, any
    free writing prospectus that we have authorized to use and the
    documents incorporated by reference herein and in the
    accompanying prospectus. You should pay special attention to the
    &#147;Risk Factors&#148; section of this prospectus supplement
    and the financial statements and other information incorporated
    by reference herein and in the accompanying prospectus
    supplement.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    Business</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a biopharmaceutical company focused on the development
    and commercialization of recombinant therapeutic proteins based
    on our proprietary
    ProCellEx<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    protein expression system, or ProCellEx. Using our ProCellEx
    system, we are developing a pipeline of proprietary and
    biosimilar or &#147;generic&#148; versions of recombinant
    therapeutic proteins based on our plant cell-based expression
    technology that target large, established pharmaceutical markets
    and that rely upon known biological mechanisms of action. Our
    initial commercial focus has been on complex therapeutic
    proteins, including proteins for the treatment of genetic
    disorders, such as Gaucher disease and Fabry disease. We believe
    our ProCellEx protein expression system will enable us to
    develop proprietary recombinant proteins that are
    therapeutically equivalent or superior to existing recombinant
    proteins currently marketed for the same indications. Because we
    are primarily targeting biologically equivalent versions of
    highly active, well-tolerated and commercially successful
    therapeutic proteins, we believe our development process is
    associated with relatively less risk compared to other
    biopharmaceutical development processes for completely novel
    therapeutic proteins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Taliglucerase alfa, our proprietary, lead product candidate, is
    a recombinant form of glucocerebrosidase (GCD) that we are
    developing for the treatment of Gaucher disease patients using
    our ProCellEx protein expression system. Gaucher disease is a
    rare and serious lysosomal storage disorder with severe and
    debilitating symptoms. Patients of Gaucher disease suffer from
    mutations in or deficiencies of GCD, which is an enzyme that is
    naturally found in human cells. In July 2007, we reached an
    agreement with the U.S.&#160;Food and Drug Administration, or
    the FDA, on the final design of our pivotal phase&#160;III
    clinical trial of taliglucerase alfa through the FDA&#146;s
    special protocol assessment process (SPA). We completed the
    phase&#160;III clinical trial of taliglucerase alfa for the
    treatment of Gaucher disease in September 2009 and, on
    October&#160;15, 2009, we announced positive top-line results
    from the trial. We originally filed a New Drug Application (NDA)
    for taliglucerase alfa on December&#160;9, 2009, and in January
    2010 the FDA requested additional data regarding the chemistry,
    manufacturing and controls (CMC)&#160;section of the NDA. We
    provided the requested data to the FDA in April 2010, and in
    July 2010 we received notification from the FDA that it had
    accepted the filing of our NDA and assigned a Prescription Drug
    User Fee Act (PDUFA) date of February&#160;25, 2011 to
    taliglucerase alfa for the treatment of Gaucher disease. In
    addition to the NDA, in November 2010 we submitted a marketing
    application to the Israeli Ministry of Health, or the Israeli
    MOH, and a Marketing Authorization Application (MAA) to each of
    the European Medicines Agency, or the EMEA, and ANVISA, the
    National Sanitary Vigilance Agency, an agency of the Brazilian
    Ministry of Health, or the ANVISA, for taliglucerase alfa for
    the treatment of Gaucher disease.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On February&#160;25, 2011, we announced that the FDA issued a
    Complete Response Letter, or a CRL, regarding our NDA for
    taliglucerase alfa for the treatment of Gaucher disease. A CRL
    is issued by the FDA&#146;s Center for Drug Evaluation and
    Research when the review of a file is completed and questions
    remain that preclude the approval of the NDA in its current
    form. The main questions raised by the FDA regarding the NDA
    relate to the clinical and CMC sections. In the clinical section
    of the CRL, the FDA requested additional data from the ongoing
    switchover trial and the long-term extension trial. At the time
    the NDA was submitted, full data from these trials was not
    available. In the CMC section of the CRL, the FDA requested
    information regarding testing specifications and assay
    validation. The FDA did not request additional clinical studies
    in the CRL. The marketing application submitted to the Israeli
    MOH and the MAAs submitted to each of the EMEA and ANVISA
    include certain data now being requested by the FDA in the CRL
    as those applications were
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    submitted approximately a year after we filed our NDA and after
    we had collected additional data from our ongoing trials. We are
    working with Pfizer Inc., or Pfizer, our commercialization
    partner, to respond to the CRL. We have already begun preparing
    our response to the CRL, with Pfizer&#146;s cooperation, and
    intend to request a meeting with the FDA as soon as possible to
    clarify the path to regulatory approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In February 2010, the Israeli MOH completed a successful good
    manufacturing practices (GMP) audit of our manufacturing
    facilities in Carmiel, Israel. The audit was performed as part
    of the Israeli MOH&#146;s evaluation of our manufacturing
    process for taliglucerase alfa. On February&#160;20, 2011, we
    received a letter from the FDA notifying us that the FDA had
    completed its review of the Establishment Inspection Report in
    connection with the FDA&#146;s inspection of our facility in
    Carmiel, Israel, and that the FDA had classified our facility as
    acceptable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to our recently completed phase&#160;III clinical
    trial, we initiated a double-blind, follow-on extension study as
    part of the trial during the second quarter of 2008. We also
    initiated a home care treatment program for patients enrolled in
    the extension study and, in December 2008, we initiated a
    nine-month, worldwide, multi-center, open-label, switch-over
    clinical study evaluating the safety and efficacy of switching
    Gaucher patients currently treated under the current standard of
    care to treatment with taliglucerase alfa. Patients in these
    trials are still being treated with taliglucerase alfa. The
    current standard of care for Gaucher patients is enzyme
    replacement therapy with Cerezyme, which is produced by Genzyme
    Corporation and, until the recent approval of VPRIV by Shire plc
    in February 2010, was the only approved enzyme replacement
    therapy for Gaucher disease. Enzyme replacement therapy is a
    medical treatment in which recombinant enzymes are infused into
    patients in whom the enzyme is lacking or dysfunctional.
    Taliglucerase alfa has an amino acid, glycan and
    three-dimensional structure that is very similar to Cerezyme,
    which is a mammalian cell expressed version of the same protein.
    We believe taliglucerase alfa may prove more cost-effective than
    the currently marketed alternatives due to the cost benefits of
    expression through our ProCellEx protein expression system.
    Although the FDA did not originally require the switch-over
    study in the SPA as a prerequisite for approval of taliglucerase
    alfa, the FDA has now requested data from the switchover trial
    in the CRL. In December 2009, we filed a proposed pediatric
    investigation plan to the Pediatric Committee of the EMEA which
    was approved during the first quarter of 2010 and have since
    initiated the study. In November 2010, we announced positive
    preliminary data from the first 15&#160;patients that completed
    the switchover clinical study of taliglucerase alfa. Only
    pediatric patient enrollment remains open for this study.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On November&#160;30, 2009, Protalix Ltd., our wholly-owned
    subsidiary, and Pfizer entered into an exclusive license and
    supply agreement pursuant to which Pfizer was granted an
    exclusive, worldwide license to develop and commercialize
    taliglucerase alfa. Under the terms and conditions of the Pfizer
    agreement, Protalix Ltd. retained the right to commercialize
    taliglucerase alfa in Israel. In connection with the execution
    of the Pfizer agreement, Pfizer made an upfront payment to
    Protalix Ltd. of $60.0&#160;million in connection with the
    execution of the agreement and subsequently paid Protalix Ltd.
    an additional $5.0&#160;million upon its filing of a proposed
    pediatric investigation plan to the Pediatric Committee of the
    EMEA. Protalix Ltd. is also eligible to receive potential
    milestone payments totaling $50.0&#160;million for the
    successful achievement of other regulatory milestones. Pfizer
    and Protalix Ltd. will also share future revenues and expenses
    for the development and commercialization of taliglucerase alfa
    on a 60% and 40% basis, respectively, and have also agreed to a
    specific allocation of the responsibilities for the continued
    development efforts for taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In July 2009, following a request by the FDA, we submitted a
    treatment protocol to the FDA in order to address an expected
    shortage of the current enzyme replacement therapy approved for
    Gaucher disease. The treatment protocol was approved by the FDA
    in August 2009, and we are continuing to treat patients in the
    United States under this protocol. In September 2009, the
    FDA&#146;s Office of Orphan Product Development granted
    taliglucerase alfa Orphan Drug Status. In January 2010, the
    Committee for Orphan Medicinal Products (COMP) of the EMEA,
    after reviewing all relevant clinical data, recommended that the
    European Commission grant Orphan Drug designation to
    taliglucerase alfa for the treatment of Gaucher disease. The
    Orphan Drug designation in the United States for taliglucerase
    alfa for the treatment of Gaucher disease provides special
    status to taliglucerase alfa provided that it meets certain
    criteria. As a result of the Orphan Drug designation, we are
    qualified for the tax credit and marketing incentives of the
    Orphan Drug Act of 1983. A marketing application for a
    prescription drug product that has been designated as a drug for
    a rare disease or condition is
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    not subject to a prescription drug user fee unless the
    application includes an indication for other than a rare disease
    or condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;13, 2010, we announced that the French regulatory
    authority had granted an Autorisation Temporaire
    d&#146;Utilisation (ATU), or Temporary Authorization for Use,
    for taliglucerase alfa for the treatment of Gaucher disease. An
    ATU is the regulatory mechanism used by the French Health
    Products and Safety Agency to make non-approved drugs available
    to patients in France when a genuine public health need exists.
    This ATU allows patients with Gaucher disease in France to
    receive treatment with taliglucerase alfa before marketing
    authorization for the product is granted in the European Union.
    Payment for taliglucerase alfa has been secured through
    government allocations to hospitals. Recently, the French
    Ministry of Health announced again that there is a shortage of
    enzyme replacement therapy for Gaucher disease, and we are
    currently providing taliglucerase alfa to patients under the
    ATU. In addition to the United States, France and Brazil,
    taliglucerase alfa is also currently being provided to Gaucher
    disease patients under special access agreements or Named
    Patient provisions in the rest of the world.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On August&#160;10, 2010, Pfizer entered into a $30&#160;million
    short-term supply agreement with the Ministry of Health of
    Brazil pursuant to which Protalix and Pfizer have provided
    taliglucerase alfa to the Ministry of Health of Brazil for the
    treatment of patients with Gaucher disease. Revenue generated
    from the Ministry of Health of Brazil will be recorded by
    Pfizer, and we are entitled to our share of the revenue in
    accordance with the terms and conditions of the Pfizer
    agreement. In addition, we and the Ministry of Health of Brazil
    are in discussions relating to a possible long-term supply
    agreement that contemplates, among other matters, providing
    certain components of our manufacturing technology to the
    Ministry of Health of Brazil for implementation by it in Brazil.
    We are currently unable to assess whether these discussions will
    result in an agreement and we can make no assurance that we will
    be able to enter into such an agreement on favorable terms, if
    at all. In any event, we do not expect to enter into a long-term
    supply agreement with the Ministry of Health of Brazil until we
    receive marketing approval of taliglucerase alfa from the FDA or
    ANVISA, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to taliglucerase alfa, we are developing an
    innovative product pipeline using our ProCellEx protein
    expression system. Our product pipeline currently includes,
    among other candidates, (1)&#160;PRX-102, a therapeutic protein
    candidate for the treatment of Fabry disease, a rare, genetic
    lysosomal disorder in humans, (2)&#160;PRX-105, a plant cell
    expressed pegylated recombinant acetylcholinesterase product
    candidate for biodefense and other indications,
    (3)&#160;pr-antiTNF, a plant cell expressed recombinant fusion
    protein made from the soluble form of the human TNF receptor
    (TNFR) and an antibody portion, which is being developed as a
    treatment of certain immune diseases such as rheumatoid
    arthritis, juvenile idiopathic arthritis, ankylosing,
    spondylitis, psoriatic arthritis and plaque psoriasis,
    (4)&#160;an orally administrated glucocerebrosidase enzyme for
    treating Gaucher patients utilizing the oral delivery of the
    recombinant enzyme produced within carrot cells and
    (5)&#160;additional undisclosed therapeutic proteins, all of
    which are currently being evaluated in animal studies. In March
    2010, we initiated a preliminary phase I clinical trial of
    PRX-105 which we completed in June 2010. We are currently
    preparing for further efficacy trials of this product candidate
    in larger animals. In our preclinical studies we utilized an
    analogue to nerve gas. However, we anticipate that we will use
    live nerve gas rather than an analogue in the proposed
    additional efficacy trials in animals. In December 2010, we held
    a pre-investigational new drug, or IND, meeting with the FDA
    with respect to PRX-102. We expect to submit an IND to the FDA
    within the next 12&#160;months in connection with an anticipated
    phase I/II study of PRX-102 and to initiate the trial once the
    IND is approved, if at all. We have also scheduled a pre-IND
    meeting with the FDA regarding our antiTNF program for March
    2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Except for the license we have granted to Pfizer, we hold the
    worldwide commercialization rights to our proprietary
    development candidates and we intend to establish an internal,
    commercial infrastructure and targeted sales force to market
    taliglucerase alfa in Israel and our other products, if
    approved, in North America, the European Union and in other
    significant markets, including Israel. In addition, we plan to
    continue evaluating potential strategic marketing partnerships.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    Corporate Information</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are incorporated under the laws of the State of Florida. Our
    principal executive offices are located at 2&#160;Snunit Street,
    Science Park, POB 455, Carmiel, 20100 Israel, and our telephone
    number is
    <FONT style="white-space: nowrap">+972&#160;(4)&#160;988-9488.</FONT>
    Our website is www.protalix.com. The information on or
    accessible through our website does not constitute part of this
    prospectus supplement or the accompanying prospectus and should
    not be relied upon in connection with making any investment in
    our securities.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<A name='E04358116'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Offering</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Issuer</TD>
    <TD></TD>
    <TD valign="bottom">
    Protalix BioTherapeutics, Inc.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Common Stock Offered by Us</TD>
    <TD></TD>
    <TD valign="bottom">
    4,000,000&#160;shares.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Common Stock to be Outstanding After This Offering</TD>
    <TD></TD>
    <TD valign="bottom">
    85,248,472&#160;shares.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Use of Proceeds</TD>
    <TD></TD>
    <TD valign="bottom">
    We expect the net proceeds from this offering to us will be
    approximately $20.6&#160;million, after deducting the
    underwriting discount and estimated offering expenses payable by
    us. We currently expect to use the net proceeds primarily to
    fund clinical trials for our product candidates, to fund our
    research and development activities, to enhance our
    manufacturing capacity and for working capital and general
    corporate purposes. See &#147;Use of Proceeds.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Risk Factors</TD>
    <TD></TD>
    <TD valign="bottom">
    Before investing in our common stock, you should carefully read
    and consider the &#147;Risk Factors&#148; beginning on
    <FONT style="white-space: nowrap">page&#160;S-6</FONT>
    of this prospectus supplement.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Trading Symbol for Our Common Stock</TD>
    <TD></TD>
    <TD valign="bottom">
    Our common stock is listed on each of the NYSE Amex and the Tel
    Aviv Stock Exchange under the symbol &#147;PLX.&#148;</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The number of shares of common stock to be outstanding after
    this offering is based on 81,248,472&#160;shares outstanding as
    of December&#160;31, 2010, and excludes as of such date:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    7,806,671&#160;shares of common stock issuable upon the exercise
    of outstanding stock options as of December&#160;31, 2010, at a
    weighted average exercise price of $3.73 per share;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an aggregate of 3,064&#160;shares of common stock reserved for
    future issuance under our 2006 Stock Incentive Plan.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358117'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Investing in our securities involves a high degree of risk.
    You should carefully consider the specific risks described below
    and the risks described in our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2010, which are
    incorporated by reference in this prospectus supplement and the
    accompanying prospectus in their entirety, together with the
    other information in this prospectus supplement, the
    accompanying prospectus and the information and documents
    incorporated by reference, before making an investment decision.
    See the section of this prospectus supplement entitled
    &#147;Where You Can Find More Information.&#148; Any of the
    risks we describe below or in the information incorporated
    herein by reference could cause our business, financial
    condition and results of operations to suffer. The market price
    of our common stock could decline if one or more of these risks
    and uncertainties develop into actual events. You could lose all
    or part of your investment.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    not obtain the necessary U.S. or worldwide regulatory approvals
    to commercialize our drug candidates in a timely manner, if at
    all, which would have a material adverse effect on our business,
    financial condition and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will need FDA approval to commercialize our drug candidates
    in the United States and approvals from foreign regulators to
    commercialize our drug candidates elsewhere. In order to obtain
    FDA approval of any of our drug candidates, we must submit to
    the FDA an NDA or a Biologic License Application (BLA)
    demonstrating that the drug candidate is safe for humans and
    effective for its intended use. This demonstration requires
    significant research and animal tests, which are referred to as
    preclinical studies, as well as human tests, which are referred
    to as clinical trials. In the European Union, we must submit an
    MAA to the EMEA. Satisfaction of the FDA&#146;s and foreign
    regulatory authorities&#146; regulatory requirements typically
    takes many years, and depends upon the type, complexity and
    novelty of the drug candidate and requires substantial resources
    for research, development and testing. In December 2009, we
    completed the filing of an NDA for taliglucerase alfa for the
    treatment of Gaucher disease and received a PDUFA date of
    February&#160;25, 2011, and in November 2010, we submitted a
    marketing application to the Israeli MOH and an MAA to each of
    the EMEA and ANVISA for taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In February 2011, we received a CRL from the FDA regarding our
    NDA for taliglucerase alfa for the treatment of Gaucher disease.
    The main questions raised by the FDA regarding the NDA relate to
    clinical and chemistry, manufacturing and controls (CMC). In the
    clinical section of the CRL, the FDA requested additional data
    from the ongoing switchover trial and the long-term extension
    trial relating to taliglucerase alfa. At the time the NDA was
    submitted, full data from these trials was not available. In the
    CMC section of the CRL, the FDA requested information regarding
    testing specifications and assay validation. The FDA did not
    request additional clinical studies in the CRL. We intend to
    request a meeting with the FDA as soon as possible to clarify
    the path to regulatory approval. Until we have further
    clarifications from the FDA regarding the CRL, we can not
    provide any details regarding our response to the CRL. In
    addition, there can be no assurance that the FDA will not make
    any additional request regarding our NDA. In the past, the FDA
    has made additional requests to other applicants after the
    delivery of a CRL. Any additional requests from the FDA relating
    to the NDA may delay or preclude our response to the CRL. Even
    if we comply with all of the FDA&#146;s requests in the CRL or
    otherwise, if any, the FDA may ultimately reject the NDA, or
    fail to approve the NDA in a timely manner, which would have a
    material adverse effect on our business, financial condition and
    results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under FDA regulations, there are two forms of resubmission of an
    NDA after receipt of a CRL. A class&#160;1 resubmission of an
    NDA following receipt of a CRL starts a new two-month review
    cycle. A class&#160;2 resubmission of an NDA starts a new
    six-month review cycle. At this time, we do not know how the FDA
    will classify resubmission we will be required to make in
    responding to the CRL. If it is classified as a class&#160;2
    resubmission, the FDA&#146;s review of the resubmission may
    result in a longer delay in the approval of taliglucerase alfa,
    if at all, which would have a material adverse effect on our
    business, financial condition and results of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our research and clinical efforts may not result in drugs that
    the FDA or foreign regulatory authorities consider safe for
    humans and effective for indicated uses, which would have a
    material adverse effect on our business, financial condition and
    results of operations. After clinical trials are completed for
    any drug candidate, if at all, the FDA and foreign regulatory
    authorities have substantial discretion in the drug approval
    process of the drug candidate in their respective jurisdictions
    and may require us to conduct additional clinical testing or to
    perform post-marketing studies which would cause us to incur
    additional costs. Incurring such costs could have a material
    adverse effect on our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The approval process for any drug candidate may also be delayed
    by changes in government regulation, future legislation or
    administrative action or changes in policy of the FDA and
    comparable foreign authorities that occur prior to or during
    their respective regulatory reviews of such drug candidate.
    Delays in obtaining regulatory approvals with respect to any
    drug candidate may:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delay commercialization of, and our ability to derive product
    revenues from, such drug candidate;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delay the regulatory-related milestone payments we anticipate
    receiving from Pfizer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require us to perform costly procedures with respect to such
    drug candidate;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    otherwise diminish any competitive advantages that we may have
    with respect to such drug candidate.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Even if we comply with all the requests of the FDA and
    comparable foreign authorities, the authorities may ultimately
    reject the NDA or other filing or submission we filed for
    taliglucerase alfa or one or more of the NDAs or other filing or
    submission we file in the future, if any, or we might not obtain
    regulatory clearance in a timely manner for taliglucerase alfa
    or any of our other product candidates. Companies in the
    pharmaceutical and biotechnology industries have suffered
    significant setbacks in advanced or late-stage clinical trials,
    even after obtaining promising earlier trial results or in
    preliminary findings or other comparable authorities for such
    clinical trials. Further, even if favorable testing data is
    generated by the clinical trials of a drug product, the FDA,
    EMEA or other regulatory authority may not accept or approve an
    NDA, MAA or other comparable submission, as applicable, filed by
    a pharmaceutical or biotechnology company for the drug product.
    Failure to obtain approval of the FDA or comparable foreign
    authorities of any of our drug candidates in a timely manner, if
    at all, will severely undermine our business, financial
    condition and results of operation by reducing our potential
    marketable products and our ability to generate corresponding
    product revenues.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    currently depend heavily on the success of taliglucerase alfa,
    our lead product candidate. Any failure to commercialize
    taliglucerase alfa, or the experience of significant delays in
    doing so, will have a material adverse effect on our business,
    financial condition and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have invested a significant portion of our efforts and
    financial resources in the development of taliglucerase alfa.
    Our ability to generate product revenue depends heavily on the
    successful development and commercialization of taliglucerase
    alfa. In November 2009, we granted to Pfizer an exclusive
    worldwide license to develop and commercialize taliglucerase
    alfa, except in Israel. We retained such rights in Israel. The
    successful commercialization of taliglucerase alfa will depend
    on several factors, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    promptly and successfully completing our response to the CRL;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtaining marketing approvals from the FDA and other foreign
    regulatory authorities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    successful completion of our ongoing studies of taliglucerase
    alfa;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    maintaining the cGMP compliance of our manufacturing facility or
    establishing manufacturing arrangements with third parties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the successful audit of our facilities by the FDA, the Israeli
    MOH and other foreign regulatory authorities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Pfizer&#146;s efforts under the Pfizer agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our development of a successful sales and marketing organization
    for taliglucerase in Israel;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the availability of reimbursement to patients from healthcare
    payors for our drug products, if approved;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a continued acceptable safety and efficacy profile of our
    product candidates following approval;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other risks described in these risk factors and those set forth
    in our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2010.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any failure to commercialize taliglucerase alfa or the
    experience of significant delays in doing so will have a
    material adverse effect on our business, financial condition and
    results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">A
    substantial number of shares may be sold in the market following
    this offering, which may depress the market price for our common
    stock.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Sales of a substantial number of shares of our common stock in
    the public market following this offering, either on the NYSE
    Amex or the Tel Aviv Stock Exchange, could cause the market
    price of our common stock to decline. Upon completion of this
    offering, based on our shares outstanding as of
    December&#160;31, 2010, we will have outstanding an aggregate of
    85,248,472 shares of common stock, assuming no exercise of
    outstanding options. A substantial majority of the outstanding
    shares of our common stock are, and all of the shares sold in
    this offering upon issuance will be, freely tradable without
    restriction or further registration under the Securities Act of
    1933, as amended, or the Securities Act, unless these shares are
    owned or purchased by &#147;affiliates&#148; as that term is
    defined in Rule&#160;144 under the Securities Act. In addition,
    we have also registered all common stock that we may issue under
    our 2006 Stock Incentive Plan, and as of December&#160;31, 2010,
    a total of 7,806,671&#160;shares of our common stock are
    issuable upon exercise of outstanding options granted by us, at
    a weighted average exercise price of $3.73 per share, and a
    total of 3,064&#160;shares of common stock remain available for
    future for issuance under such plan. As a result, these shares
    can be freely sold in the public market upon issuance, subject
    to restrictions under the securities laws. In addition, four of
    our executive officers have entered into trading plans
    established under
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Securities Act that allow for sales of approximately
    1.3&#160;million shares upon receipt of FDA approval of
    taliglucerase alfa, if at all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    use the net proceeds of this offering in ways with which you may
    disagree.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We intend to use the net proceeds of this offering to raise
    capital to fund clinical trials for our product candidates, to
    fund our research and development activities, to enhance our
    manufacturing capacity and for working capital and general
    corporate purposes. As of the date of this prospectus
    supplement, we cannot specify with certainty all of the
    particular uses of the proceeds from this offering. Accordingly,
    we will have significant discretion in the use of the net
    proceeds of this offering. It is possible that we may allocate
    the proceeds differently than investors in this offering desire
    or that we will fail to maximize our return on these proceeds.
    We may, subsequent to this offering, modify our intended use of
    the offering proceeds to pursue strategic opportunities that may
    arise, such as potential acquisition opportunities. You will be
    relying on the judgment of our management with regard to the use
    of the net proceeds of this offering, and you will not have the
    opportunity, as part of your investment decision, to assess
    whether the proceeds are being used appropriately. Our failure
    to apply the net proceeds of this offering effectively could
    have a material adverse effect on our business or the
    commercialization of taliglucerase alfa, if approved by the FDA,
    and cause the price of our common stock to decline.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">You
    will experience immediate dilution in the net tangible book
    value of the shares of our common stock you purchase as a result
    of this offering.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you purchase shares of our common stock in this offering, you
    will pay more for your shares than the net tangible book value
    per share of our common stock as of December&#160;31, 2010. As a
    result, the value of your investment based on the net tangible
    book value per share of our common stock will be less than what
    it would have been had you and all of the existing stockholders
    paid the same amount per share of common stock as you will pay
    in this offering. Since the price per share of our common stock
    being offered is substantially higher than the net tangible book
    value per share of our common stock, you will suffer substantial
    dilution in the net tangible book value of the common stock you
    purchase in this offering. The
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    exercise of outstanding options into common stock and future
    issuances by us of equity or convertible debt may result in
    further dilution to your investment in our common stock. See
    &#147;Dilution.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">You
    may experience future dilution as a result of future equity
    offerings or other equity issuances.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In order to raise additional capital, we may in the future offer
    and issue additional shares of our common stock or other
    securities convertible into or exchangeable for our common
    stock. We cannot assure you that we will be able to sell shares
    or other securities in any other offering at a price per share
    that is equal to or greater than the price per share paid by
    investors in this offering, and investors purchasing shares or
    other securities in the future could have rights superior to
    existing stockholders. The price per share at which we sell
    additional shares of our common stock or other securities
    convertible into or exchangeable for our common stock in future
    transactions may be higher or lower than the price per share in
    this offering. As of December&#160;31, 2010, an aggregate of
    3,064&#160;shares of common stock were reserved and available
    for future grant under our 2006 Stock Incentive Plan. Also as of
    such date, options to purchase 7,806,671&#160;shares of our
    common stock were outstanding. You will incur dilution upon the
    grant of any shares pursuant to such plan, upon vesting of any
    stock awards under any such plan, or upon exercise of any such
    outstanding options.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358118'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CAUTIONARY
    STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The statements set forth and incorporated by reference in this
    prospectus supplement and the accompanying prospectus, which are
    not historical, constitute &#147;forward looking
    statements&#148; within the meaning of Section&#160;27A of the
    Securities Act and Section&#160;21E of the Securities Exchange
    Act of 1934, as amended, or the Exchange Act, including
    statements regarding the expectations, beliefs, intentions or
    strategies for the future. When used in this prospectus
    supplement and the accompanying prospectus, or in any document
    incorporated by reference in this prospectus supplement or the
    accompanying prospectus, the terms &#147;anticipate,&#148;
    &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148;
    &#147;intend,&#148; &#147;could,&#148; &#147;may,&#148;
    &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
    &#147;project,&#148; &#147;should,&#148; &#147;will,&#148;
    &#147;would&#148; and words or phrases of similar import, as
    they relate to us, or our subsidiaries or our management, are
    intended to identify forward-looking statements, although not
    all forward-looking statements contain these words. We intend
    that all forward-looking statements be subject to the
    safe-harbor provisions of the Private Securities Litigation
    Reform Act of 1995. Forward-looking statements include, but are
    not limited to, statements about our expectations as to
    regulatory approvals, submissions of regulatory filings, market
    opportunity for our product candidates, goals as to product
    candidate development and timeliness of our clinical trials.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Forward-looking statements are subject to many risks and
    uncertainties that could cause our actual results to differ
    materially from any future results expressed or implied by the
    forward-looking statements. Example of the risks and
    uncertainties include, but are not limited to, the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in our response to the CRL we received from the FDA
    relating to our NDA for taliglucerase alfa;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in the FDA&#146;s review of any response to the CRL, if
    any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in the approval or the potential rejection of any
    applications we file with the FDA or other regulatory
    authorities, including the NDA we have filed with the FDA, the
    marketing application we submitted to the Israeli MOH and the
    MAA we have submitted to each of the EMEA and ANVISA for
    taliglucerase alfa;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the inherent risks and uncertainties in developing the types of
    drug platforms and products we are developing;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in our preparation and filing of applications for
    regulatory approval in the United States, the European Union,
    Israel, Brazil and elsewhere;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any lack of progress of our research and development (including
    the results of our clinical trials);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to establish and maintain strategic license,
    collaboration and distribution arrangements and to manage our
    relationships with Pfizer, Teva Ltd. or with any other
    collaborator, distributor or partner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to obtain on a timely basis sufficient patient
    enrollment in our clinical trials;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the impact of development of competing therapies
    <FONT style="white-space: nowrap">and/or</FONT>
    technologies by other companies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    risks relating to biogeneric legislation and/or healthcare
    reform in the United States or elsewhere;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to obtain additional financing required to fund our
    research programs and the expansion of our manufacturing
    capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risk that we will not be able to develop a successful sales
    and marketing organization in a timely manner, if at all;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to enter into supply arrangements with the Ministry
    of Health of Brazil or other parties and to supply drug product
    pursuant to such arrangements;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potential product liability risks, and risks of securing
    adequate levels of product liability and clinical trial
    insurance coverage;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the availability of reimbursement to patients from health care
    payors for any of our product candidates, if approved;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possibility of infringing a third party&#146;s patents or
    other intellectual property rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the uncertainty of obtaining patents covering our products and
    processes and in successfully enforcing our intellectual
    property rights against third parties;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possible disruption of our operations due to terrorist
    activities and armed conflict, including as a result of the
    disruption of the operations of regulatory authorities, our
    subsidiaries, our manufacturing facilities and our customers,
    suppliers, distributors, collaborative partners, licensees and
    clinical trial sites.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In February 2011, we received a CRL from the FDA regarding our
    NDA for taliglucerase alfa for the treatment of Gaucher disease.
    The main questions raised by the FDA regarding the NDA relate to
    the clinical and CMC sections. In the clinical section of the
    CRL, the FDA requested additional data from each of the
    switchover trial and the long-term extension trial. In the CMC
    section of the CRL, the FDA requested information regarding
    testing specifications and assay validation. The FDA did not
    request additional clinical studies in the CRL. Until we have
    further clarifications from the FDA regarding the CRL, there can
    be no assurance that the FDA will not make any additional
    request regarding our NDA. In the past, the FDA has made
    additional requests to other applicants after the delivery of a
    CRL. Any additional requests from the FDA relating to the NDA
    may delay or preclude our response to the CRL. Even if we comply
    with all of the FDA&#146;s requests in the CRL, or otherwise if
    any, the FDA may ultimately reject the NDA, or fail to approve
    the NDA in a timely manner, which would have a material adverse
    effect on our business, financial condition and results of
    operations. In addition, if we are required to make a
    class&#160;2 resubmission in response to the CRL, the FDA&#146;s
    review of the resubmission may result in a longer delay in the
    approval of taliglucerase alfa, if at all, which would have a
    material adverse effect on our business, financial condition and
    results of operations. Our efforts to respond to the CRL, and
    any development with the FDA with respect to our response, may
    result in changes to our current expectations as reflected in
    our forward-looking statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    These forward-looking statements reflect our current views with
    respect to future events and are based on assumptions and
    subject to risks and uncertainties. Given these uncertainties,
    you should not place undue reliance on these forward-looking
    statements. These and other risks and uncertainties are detailed
    under the heading &#147;Risk Factors&#148; beginning on
    <FONT style="white-space: nowrap">page&#160;S-6</FONT>
    of this prospectus supplement, in our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2010, Section&#160;1A,
    under the heading &#147;Risk Factors,&#148; and described from
    time to time in our future reports to be filed with the SEC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any or all of our forward-looking statements are only
    predictions and reflect our views as of the date they are made
    with respect to future events and financial performance and we
    undertake no obligation to update or revise, nor do we have a
    policy of updating or revising, any forward-looking statement to
    reflect events or circumstances after the date on which the
    statement is made or to reflect the occurrence of unanticipated
    events, except as may be required under applicable law.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358119'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We estimate that the net proceeds we will receive from this
    offering will be approximately $20.6&#160;million after
    deducting the underwriting discount and estimated offering
    expenses payable by us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We currently expect to use the net proceeds of this offering to
    fund clinical trials for our product candidates; to fund our
    research and development activities; to enhance our
    manufacturing capacity; and for working capital and general
    corporate purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The foregoing information is based on our current business plan.
    As of the date of this prospectus supplement, we cannot specify
    with certainty all of the particular uses of the net proceeds of
    this offering. We may find it necessary to shift funds reserved
    for one category of uses to another purpose. For example, we
    may, subsequent to this offering, pursue strategic opportunities
    that may arise, such as potential acquisition opportunities,
    although we have no current plans, commitments or agreements to
    do so as of the date of this prospectus supplement. We have
    broad discretion and may find it necessary or advisable to
    re-allocate portions of the net proceeds of this offering. The
    amounts and timing of our actual expenditures will depend on
    numerous factors, including the status of the FDA&#146;s, the
    EMEA&#146;s and other regulatory authorities&#146; review of
    taliglucerase alfa, our product development and
    commercialization efforts, our sales and marketing activities,
    the amount of cash used by our operations and our assessment of
    the ability to add long-term shareholder value through potential
    strategic opportunities. Investors will be relying on the
    judgment of our management regarding the application of these
    net proceeds. Pending these uses, we intend to invest the net
    proceeds of the offering in short-term bank deposits or
    marketable securities.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358120'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PRICE
    RANGE OF COMMON STOCK</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock began trading on the NYSE Amex on
    March&#160;12, 2007 under the symbol &#147;PLX.&#148; The
    following table sets forth, for the periods indicated, the high
    and low closing prices for our common stock, as reported by the
    NYSE Amex for the periods indicated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="85%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price Range</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>High</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Low</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Annual:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Quarterly:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Quarter 2011 (through March&#160;17)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fourth Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Third Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Second Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fourth Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Third Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.51
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Second Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fourth Quarter 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Third Quarter 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.08
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Second Quarter 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Quarter 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.59
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.59
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Most Recent Six Months:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    March 2011 (through March&#160;17)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.04
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    February 2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    January 2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    December 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.67
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    November 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    October 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    September 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock began trading on the Tel Aviv Stock Exchange on
    September&#160;6, 2010 under the symbol &#147;PLX.&#148; The
    following table sets forth, for the periods indicated, the high
    and low closing prices for our common stock in Israeli New
    Shekels (NIS) and U.S.&#160;dollars. U.S.&#160;dollar per share
    of common stock amounts are calculated using the
    U.S.&#160;dollar representative rate of exchange on the date to
    which the high or low market price is applicable, as reported by
    the Bank of Israel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price Range (NIS)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price Range&#160;($)</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>High</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Low</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>High</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Low</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Annual:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010 (from September 6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 36.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 30.95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Quarterly:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Quarter 2011 (through March&#160;17)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 38.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 21.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fourth Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 36.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 31.04
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Third Quarter 2010 (from September 6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 32.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 30.95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Most Recent Six Months:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    March 2011 (through March&#160;17)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 25.51
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 21.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.04
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    February 2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 38.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 26.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    January 2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 37.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 33.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    December 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 35.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 31.88
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    November 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 36.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 31.04
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    October 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 35.78
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 32.58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    September 2010 (from September 6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 32.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    NIS 30.95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358121'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CAPITALIZATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table presents our capitalization as of
    December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an actual basis;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an as adjusted basis to reflect the sale of
    4,000,000&#160;shares of common stock at the public offering
    price of $5.50 per share, the receipt by us of net proceeds of
    approximately $20.6&#160;million, after deducting the
    underwriting discount and the estimated offering expenses
    payable by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This table should be read in conjunction with our financial
    statements and the notes thereto incorporated by reference
    herein and the accompanying prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As Adjusted</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(in thousands, except share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts payable and accruals (trade and other)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Short-term deferred revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,563
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,563
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term deferred revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Liability for employee rights upon retirement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,052
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,052
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shareholders&#146; equity:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common stock, par value $.001 per share; 150,000,000 authorized
    shares, 81,248,472 issued and outstanding shares, actual;
    85,248,472 issued and outstanding shares, as adjusted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    124,044
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    144,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135,448
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135,448
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total shareholders&#146; equity (capital deficiency)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total capitalization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    64,729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    85,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The number of as adjusted shares of common stock in the above
    table excludes, as of December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    7,806,671&#160;shares of common stock issuable upon the exercise
    of outstanding stock options as of December&#160;31, 2010, at a
    weighted average exercise price of $3.73 per share;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an aggregate of 3,064&#160;shares of common stock reserved for
    future issuance under our 2006 Stock Incentive Plan.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358128'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you invest in our common stock, your interest will be diluted
    immediately to the extent of the difference between the public
    offering price per share of our common stock and the as adjusted
    net tangible book value per share of common stock after this
    offering.
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The net tangible book value (deficit) of our common stock as of
    December&#160;31, 2010 was approximately $(11.3)&#160;million,
    or approximately $(0.14) per share. Net tangible book value per
    share represents the amount of our total tangible assets less
    total liabilities divided by the total number of shares of our
    common stock outstanding.
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Dilution per share to new investors represents the difference
    between the amount per share paid by purchasers for our common
    stock in this offering and the net tangible book value per share
    of our common stock immediately following the completion of this
    offering.
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After giving effect to the sale of shares of common stock
    offered by this prospectus supplement at the public offering
    price of $5.50&#160;per share in connection with this offering
    and after deducting the underwriting discount and estimated
    offering expenses payable by us, our as adjusted net tangible
    book value as of December&#160;31, 2010 would have been
    approximately $9.27&#160;million, or approximately
    $0.11&#160;per share. This represents an immediate increase in
    net tangible book value of approximately $0.25&#160;per share to
    our existing stockholders and an immediate dilution in as
    adjusted net tangible book value of approximately $5.39&#160;per
    share to purchasers of our common stock in this offering, as
    illustrated by the following table:
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Public offering price per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net tangible book value (deficit) per share as of
    December&#160;31, 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.14
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in per share attributable to investors purchasing our
    common stock in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As adjusted net tangible book value per share as of
    December&#160;31, 2010 after giving effect to this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dilution per share to investors purchasing our common stock in
    this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The number of shares of common stock to be outstanding after
    this offering is based on 81,248,472&#160;shares outstanding as
    of December&#160;31, 2010 and excludes as of such date:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    7,806,671&#160;shares of common stock issuable upon the exercise
    outstanding stock options as of December&#160;31, 2010, at a
    weighted average exercise price of $3.73 per share;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an aggregate of 3,064&#160;shares of common stock reserved for
    future issuance under our 2006 Stock Incentive Plan.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To the extent that outstanding options are exercised, you will
    experience further dilution. In addition, we may choose to raise
    additional capital due to market conditions or strategic
    considerations even if we believe we have sufficient funds for
    our current or future operating plans. To the extent that
    additional capital is raised through the sale of equity or
    convertible debt securities, the issuance of these securities
    could result in further dilution to our stockholders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358122'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES TO<BR>
    <FONT style="white-space: nowrap">NON-U.S.</FONT>
    HOLDERS OF COMMON STOCK</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following is a summary of certain U.S.&#160;federal income
    tax consequences of the purchase, ownership, and disposition of
    common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (as defined below) that acquires our common stock in this
    offering and holds it as a capital asset. This discussion is
    based upon the Internal Revenue Code of 1986, as amended, which
    we refer to as the Code, effective U.S.&#160;Treasury
    regulations, and judicial decisions and administrative
    interpretations thereof, all as of the date hereof and all of
    which are subject to change, possibly with retroactive effect.
    The foregoing are subject to differing interpretations which
    could affect the tax consequences described herein. This
    discussion does not address all aspects of U.S.&#160;federal
    income taxation that may be applicable to investors in light of
    their particular circumstances, or to investors subject to
    special treatment under U.S.&#160;federal income tax laws, such
    as financial institutions, insurance companies, tax-exempt
    organizations, entities that are treated as partnerships for
    U.S.&#160;federal income tax purposes, dealers in securities or
    currencies, expatriates, persons deemed to sell common stock
    under the constructive sale provisions of the Code, and persons
    that hold common stock as part of a straddle, hedge, conversion
    transaction, or other integrated investment. Furthermore, this
    discussion does not address any state, local or foreign tax laws.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">You are
    urged to consult your tax advisors regarding the U.S. federal,
    state, local, and foreign income and other tax consequences of
    the purchase, ownership, and disposition of our common stock,
    including the consequences under any applicable tax
    treaty.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of this summary, you are a
    <FONT style="white-space: nowrap">&#147;non-U.S.&#160;holder&#148;</FONT>
    if you are a beneficial owner of common stock that, for
    U.S.&#160;federal income tax purposes, is not:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual that is a citizen or resident of the United States;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation, other entity treated as a corporation for
    U.S.&#160;federal income tax purposes, or partnership that is
    created or organized under the laws of the United States, any
    state thereof, or the District of Columbia;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate the income of which is subject to U.S.&#160;federal
    income taxation regardless of its source;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust, provided that, (1)&#160;a court within the United
    States is able to exercise primary supervision over its
    administration or one or more U.S.&#160;persons (as defined in
    the Code) have the authority to control all substantial
    decisions of that trust, or (2)&#160;the trust has made an
    election under the applicable Treasury regulations to be treated
    as a U.S.&#160;person.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If a partnership (including any entity or arrangement treated as
    a partnership for U.S.&#160;federal income tax purposes) owns
    our common stock, the U.S.&#160;federal income tax treatment of
    a partner in the partnership generally will depend upon the
    status of the partner and the activities of the partnership.
    Partners in a partnership that owns our common stock should
    consult their tax advisors as to the particular
    U.S.&#160;federal income tax consequences applicable to them.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Except as described below, if you are a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of common stock, dividends paid to you are subject to
    withholding of U.S.&#160;federal income tax at a 30% rate or at
    a lower rate if you are eligible for the benefits of an income
    tax treaty that provides for a lower rate. Even if you are
    eligible for a lower treaty rate, we and other payors will
    generally be required to withhold at a 30% rate (rather than the
    lower treaty rate) on dividend payments to you, unless you have
    furnished to us or another payor:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a valid Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8BEN</FONT>
    or an acceptable substitute form upon which you certify, under
    penalties of perjury, your status as (or, in the case of a
    U.S.&#160;alien holder that is a partnership or an estate or
    trust, such forms certifying the status of each partner in the
    partnership or beneficiary of the estate or trust as) a non-
    U.S.&#160;person and your entitlement to the lower treaty rate
    with respect to such payments;&#160;or
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the case of payments made outside the United States to an
    offshore account (generally, an account maintained by you at an
    office or branch of a bank or other financial institution at any
    location outside the United States), other documentary evidence
    establishing your entitlement to the lower treaty rate in
    accordance with U.S.&#160;Treasury regulations.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Special certification and other requirements apply to certain
    <FONT style="white-space: nowrap">non-U.S.&#160;holders</FONT>
    that are pass-through entities rather than companies or
    individuals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you are eligible for a reduced rate of U.S.&#160;withholding
    tax under a tax treaty, you may obtain a refund of any amounts
    withheld in excess of that rate by filing a refund claim with
    the U.S.&#160;Internal Revenue Service.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If dividends paid to you are &#147;effectively connected&#148;
    with your conduct of a trade or business within the United
    States, and you have not claimed the dividends are eligible for
    any treaty benefits as income that is not attributable to a
    permanent establishment that you maintain in the United States,
    we and other payors generally are not required to withhold tax
    from the dividends, provided that you have furnished to us or
    another payor a valid Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8ECI</FONT>
    or an acceptable substitute form upon which you certify, under
    penalties of perjury, that you are a non-U.S.&#160;person, and
    the dividends are effectively connected with your conduct of a
    trade or business within the United States and are includible in
    your gross income. &#147;Effectively connected&#148; dividends
    are taxed at rates applicable to U.S.&#160;persons on a net
    income basis. If you are a corporate
    <FONT style="white-space: nowrap">non-U.S.&#160;holder,</FONT>
    &#147;effectively connected&#148; dividends that you receive
    may, under certain circumstances, be subject to an additional
    &#147;branch profits tax&#148; at a 30% rate or at a lower rate
    if you are eligible for the benefits of an income tax treaty
    that provides for a lower rate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Disposition
    of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you are a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder,</FONT>
    you generally will not be subject to U.S.&#160;federal income
    tax on gain from U.S.&#160;sources that you recognize on a
    disposition of our common stock unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the gain is &#147;effectively connected&#148; with your conduct
    of a trade or business in the United States, and the gain is
    attributable to a permanent establishment that you maintain in
    the United States, if that is required by an applicable income
    tax treaty as a condition for subjecting you to
    U.S.&#160;taxation on a net income basis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    you are an individual and you are present in the United States
    for 183 or more days in the taxable year of the
    disposition;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we have been a &#147;United States real property holding
    corporation,&#148; or USRPHC, for U.S.&#160;federal income tax
    purposes at any time within the shorter of the five-year period
    preceding your disposition of our common stock or your holding
    period for our common stock.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    &#147;Effectively connected&#148; gains are taxed at rates
    applicable to U.S.&#160;persons on a net income tax basis. If
    you are a corporate
    <FONT style="white-space: nowrap">non-U.S.&#160;holder,</FONT>
    &#147;effectively connected&#148; gains that you recognize may
    also, under certain circumstances, be subject to an additional
    &#147;branch profits tax&#148; at a 30% rate or at a lower rate
    if you are eligible for the benefits of an income tax treaty
    that provides for a lower rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    An individual
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    described in the second bullet point above will only be subject
    to U.S.&#160;federal income tax on the gain from the sale of our
    common stock to the extent such gain is deemed to be from
    U.S.&#160;sources, which will generally only be the case where
    the individual&#146;s tax home is in the United States. An
    individual&#146;s tax home is generally considered to be located
    at the individual&#146;s regular or principal (if more than one
    regular) place of business. If the individual has no regular or
    principal place of business because of the nature of the
    business, or because the individual is not engaged in carrying
    on any trade or business, then the individual&#146;s tax home is
    his regular place of abode. If an individual
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is described in the second bullet point above, and the
    individual
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    tax home is in the United States, then the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    may be subject to a flat 30% tax on the gain derived from the
    disposition, which gain may be offset by
    <FONT style="white-space: nowrap">U.S.-source</FONT>
    capital losses.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe we currently are not, and we do not anticipate
    becoming, a USRPHC for U.S.&#160;federal income tax purposes.
    However, because the determination of whether we are a USRPHC
    depends on the fair market value of our United States real
    property interests relative to the fair market value of our
    other trade or business assets and our foreign real property
    interests, there can be no assurance that we will not become a
    USRPHC in the future. Even if we are or become a USRPHC, as long
    as our common stock is regularly traded on an established
    securities market, such common stock will be treated as a United
    States real property interest with respect to you only if you
    actually or constructively held more than 5% of such regularly
    traded common stock during the applicable period.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Federal
    Estate Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Common stock held by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    at the time of death generally will be included in the
    holder&#146;s gross estate for U.S.&#160;federal estate tax
    purposes, unless an applicable estate tax treaty provides
    otherwise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Information
    Reporting and Backup Withholding</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We must report annually to the Internal Revenue Service and to
    each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    the amount of dividends paid to such holder and the tax withheld
    with respect to such dividends, regardless of whether
    withholding was required. Copies of the information returns
    reporting such dividends and withholding may also be made
    available to the tax authorities in the country in which the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    resides under the provisions of an applicable income tax treaty.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to backup withholding for dividends paid to such
    holder unless such holder certifies under penalty of perjury
    that it is a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and the payor does not have actual knowledge or reason to know
    that such holder is a U.S.&#160;person as defined under the
    Code), or such holder otherwise establishes an exemption.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Information reporting and, depending on the circumstances,
    backup withholding will apply to the proceeds of a sale of our
    common stock within the United States or conducted through
    certain
    <FONT style="white-space: nowrap">U.S.-related</FONT>
    financial intermediaries, unless the beneficial owner certifies
    under penalty of perjury that it is a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and the payor does not have actual knowledge or reason to know
    that the beneficial owner is a U.S.&#160;person as defined under
    the Code), or such owner otherwise establishes an exemption.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any amounts withheld under the backup withholding rules may be
    allowed as a refund or a credit against a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    U.S.&#160;federal income tax liability provided the required
    information is furnished to the Internal Revenue Service.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Legislation
    Affecting Taxation of Common Stock Held By or Through Foreign
    Entities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Legislation was enacted on March&#160;18, 2010 that will,
    effective for payments made after December&#160;31, 2012, impose
    a 30% U.S.&#160;withholding tax on dividends paid by
    U.S.&#160;issuers and on the gross proceeds from the disposition
    of stock paid to a foreign financial institution, unless such
    institution enters into an agreement with the U.S.&#160;Treasury
    to collect and provide to the U.S.&#160;Treasury substantial
    information regarding U.S.&#160;account holders with such
    institution, including certain account holders that are foreign
    entities with U.S.&#160;owners. The legislation also generally
    imposes a withholding tax of 30% on dividends paid by
    U.S.&#160;issuers and on the gross proceeds from the disposition
    of stock paid to a non-financial foreign entity unless such
    entity provides the withholding agent with a certification that
    it does not have any substantial U.S.&#160;owners or a
    certification identifying the direct and indirect substantial
    U.S.&#160;owners of the entity. Under certain circumstances, a
    holder may be eligible for refunds or credits of such taxes.
    Investors are urged to consult with their own tax advisors
    regarding the possible implications of this recently enacted
    legislation on their investment in the common stock.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358123'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">UNDERWRITING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Citigroup Global Markets Inc. and Barclays Capital Inc. are
    acting as joint book-running managers of the offering. Subject
    to the terms and conditions stated in the underwriting agreement
    dated the date of this prospectus supplement, each underwriter
    named below has severally agreed to purchase, and we have agreed
    to sell to that underwriter, the number of shares set forth
    opposite the underwriter&#146;s name.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Underwriter</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Citigroup Global Markets Inc.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Barclays Capital Inc.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,800,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The underwriting agreement provides that the obligations of the
    underwriters to purchase the shares included in this offering
    are subject to approval of legal matters by counsel and to other
    conditions. The underwriters are obligated to purchase all the
    shares if they purchase any of the shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Shares sold by the underwriters to the public will initially be
    offered at the public offering price set forth on the cover of
    this prospectus supplement. Any shares sold by the underwriters
    to securities dealers may be sold at a discount from the public
    offering price not to exceed $0.198 per share. If all the shares
    are not sold at the public offering price, the underwriters may
    change the offering price and the other selling terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We and our officers and directors have agreed that, for a period
    of 90&#160;days from the date of this prospectus supplement, we
    and they will not, without the prior written consent of
    Citigroup Global Markets Inc. and Barclays Capital Inc., dispose
    of or hedge any shares or any securities convertible into or
    exchangeable for our common stock. Citigroup Global Markets Inc.
    and Barclays Capital Inc. in their sole discretion may release
    any of the securities subject to these
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements at any time without notice. The foregoing
    restrictions do not apply to certain transactions, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions relating to shares of common stock or other
    securities acquired in the open market after the completion of
    the offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    bona fide gifts;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    bona fide gifts, sales or other dispositions of shares of any
    class of our capital stock, in each case that are made
    exclusively between and among the undersigned or members of the
    undersigned&#146;s immediate family (or a trust to their
    benefit), or affiliates of the undersigned, including its
    partners (if a partnership) or members (if a limited liability
    company);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise of warrants or the exercise of stock options
    granted pursuant to our stock option/incentive plans or
    otherwise outstanding on the date hereof; provided, that the
    restrictions shall apply to shares of common stock issued upon
    such exercise or conversion;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the establishment of any contract, instruction or plan
    (individually, a &#147;Plan&#148; and collectively,
    &#147;Plans&#148;) that satisfies all of the requirements of
    <FONT style="white-space: nowrap">Rule&#160;10b5-1(c)(1)(i)(B)</FONT>
    under the Exchange Act; provided, however, that no sales of
    common stock or securities convertible into, or exchangeable or
    exercisable for, common stock, shall be made pursuant to a Plan
    prior to the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    period (as the same may be extended pursuant to the provisions
    hereof).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notwithstanding the foregoing, if (i)&#160;during the last
    17&#160;days of the
    <FONT style="white-space: nowrap">90-day</FONT>
    restricted period, we issue an earnings release or material news
    or a material event relating to our company occurs; or
    (ii)&#160;prior to the expiration of the
    <FONT style="white-space: nowrap">90-day</FONT>
    restricted period, we announce that we will release earnings
    results during the
    <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the
    <FONT style="white-space: nowrap">90-day</FONT>
    restricted period, the restrictions described above shall
    continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release or the
    occurrence of the material news or material event.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The shares are listed on the NYSE Amex and on the Tel Aviv Stock
    Exchange, both under the symbol &#147;PLX.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table shows the underwriting discount that we are
    to pay to the underwriters in connection with this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Paid by the Company</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,320,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with the offering, the underwriters may purchase
    and sell shares in the open market. Purchases and sales in the
    open market may include short sales, purchases to cover short
    positions and stabilizing purchases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Short sales involve secondary market sales by the underwriters
    of a greater number of shares than they are required to purchase
    in the offering.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;Covered&#148; short sales are sales of shares in an amount
    up to the number of shares represented by an underwriters&#146;
    over-allotment option, if any.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;Naked&#148; short sales are sales of shares in an amount
    in excess of the number of shares represented by an
    underwriters&#146; over-allotment option, if any.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Covering transactions involve purchases of shares either
    pursuant to an over-allotment option, if any, or in the open
    market after the distribution has been completed in order to
    cover short positions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To close a naked short position, the underwriters must purchase
    shares in the open market after the distribution has been
    completed. A naked short position is more likely to be created
    if the underwriters are concerned that there may be downward
    pressure on the price of the shares in the open market after
    pricing that could adversely affect investors who purchase in
    the offering.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To close a covered short position, the underwriters must
    purchase shares in the open market after the distribution has
    been completed or must exercise an over-allotment option, if
    any. In determining the source of shares to close the covered
    short position, the underwriters will consider, among other
    things, the price of shares available for purchase in the open
    market as compared to the price at which they may purchase
    shares through an over-allotment option, if any.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Stabilizing transactions involve bids to purchase shares so long
    as the stabilizing bids do not exceed a specified maximum.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In this offering, the underwriters have not been granted an
    over-allotment option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Purchases to cover short positions and stabilizing purchases, as
    well as other purchases by the underwriters for their own
    accounts, may have the effect of preventing or retarding a
    decline in the market price of the shares. They may also cause
    the price of the shares to be higher than the price that would
    otherwise exist in the open market in the absence of these
    transactions. The underwriters may conduct these transactions on
    the NYSE Amex, in the
    <FONT style="white-space: nowrap">over-the-counter</FONT>
    market or otherwise. If the underwriters commence any of these
    transactions, they may discontinue them at any time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The underwriters may, from time to time, engage in transactions
    with and perform services for us in the ordinary course of their
    business for which they may receive customary fees and
    reimbursement of expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have agreed to indemnify the underwriters against certain
    liabilities, including liabilities under the Securities Act, or
    to contribute to payments the underwriters may be required to
    make because of any of those liabilities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Notice to
    Prospective Investors in the European Economic Area</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In relation to each member state of the European Economic Area
    that has implemented the Prospectus Directive (each, a relevant
    member state), with effect from and including the date on which
    the Prospectus Directive is implemented in that relevant member
    state (the relevant implementation date), an offer to the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    public of shares of our common stock described in this
    prospectus supplement may not be made to the public in that
    relevant member state prior to the publication of a prospectus
    in relation to the shares of our common stock that has been
    approved by the competent authority in that relevant member
    state or, where appropriate, approved in another relevant member
    state and notified to the competent authority in that relevant
    member state, all in accordance with the Prospectus Directive,
    except that, with effect from and including the relevant
    implementation date, an offer of shares of our common stock may
    be made to the public in that relevant member state at any time:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to any legal entity which is a qualified investor as defined in
    the Prospectus Directive;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to fewer than 100 or, if the Relevant Member State has
    implemented the relevant provision of the 2010 PD Amending
    Directive, 150, natural or legal persons (other than qualified
    investors as defined in the Prospectus Directive), as permitted
    under the Prospectus Directive, subject to obtaining the prior
    consent of the underwriters for any such offer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in any other circumstances falling within Article&#160;3(2) of
    the Prospectus Directive.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of this provision, the expression an &#147;offer to
    the public&#148; in any relevant member state means the
    communication in any form and by any means of sufficient
    information on the terms of the offer and any shares of our
    common stock to be offered so as to enable an investor to decide
    to purchase or subscribe for shares of our common stock, as the
    expression may be varied in that member state by any measure
    implementing the Prospectus Directive in that member state, and
    the expression &#147;Prospectus Directive&#148; means Directive
    2003/71/EC (and amendments thereto, including the 2010 PD
    Amending Directive, to the extent implemented in the Relevant
    Member State), and includes any relevant implementing measure in
    each relevant member state and the expression 2010 PD Amending
    Directive means Directive 2010/73/EU.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This EEA selling restriction is in addition to any other selling
    restrictions set out in this prospectus supplement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Notice to
    Prospective Investors in the United Kingdom</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus supplement and the accompanying prospectus are
    only being distributed to, and is only directed at, persons in
    the United Kingdom that are qualified investors within the
    meaning of Article&#160;2(1)(e) of the Prospectus Directive that
    are also (i)&#160;investment professionals falling within
    Article&#160;19(5) of the Financial Services and Markets Act
    2000 (Financial Promotion) Order 2005 (the &#147;Order&#148;) or
    (ii)&#160;high net worth entities, and other persons to whom it
    may lawfully be communicated, falling within
    Article&#160;49(2)(a) to (d)&#160;of the Order (each such person
    being referred to as a &#147;relevant person&#148;). This
    prospectus supplement, the accompanying prospectus and their
    contents are confidential and should not be distributed,
    published or reproduced (in whole or in part) or disclosed by
    recipients to any other persons in the United Kingdom. Any
    person in the United Kingdom that is not a relevant person
    should not act or rely on this document or any of its contents.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Notice to
    Prospective Investors in France</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Neither this prospectus supplement, the accompanying prospectus
    nor any other offering material relating to the shares described
    in this prospectus supplement and the accompanying prospectus
    has been submitted to the clearance procedures of the
    <I>Autorit&#233; des March&#233;s Financiers </I>or of the
    competent authority of another member state of the European
    Economic Area and notified to the <I>Autorit&#233; des
    March&#233;s Financiers. </I>The shares have not been offered or
    sold and will not be offered or sold, directly or indirectly, to
    the public in France. Neither this prospectus supplement, the
    accompanying prospectus nor any other offering material relating
    to the shares has been or will be:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    released, issued, distributed or caused to be released, issued
    or distributed to the public in France;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    used in connection with any offer for subscription or sale of
    the shares to the public in France.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Such offers, sales and distributions will be made in France only:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to qualified investors (<I>investisseurs qualifi&#233;s</I>)
    <FONT style="white-space: nowrap">and/or</FONT> to a
    restricted circle of investors (<I>cercle restreint
    d&#146;investisseurs</I>), in each case investing for their own
    account, all as defined in, and in accordance with
    <FONT style="white-space: nowrap">articles&#160;L.411-2,</FONT>
    D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1 of the
    French <I>Code mon&#233;taire et financier</I>;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to investment services providers authorized to engage in
    portfolio management on behalf of third parties;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in a transaction that, in accordance with
    <FONT style="white-space: nowrap">article&#160;L.411-2-II-1&#176;-or-2&#176;-or</FONT>
    3&#176; of the French <I>Code mon&#233;taire et financier
    </I>and
    <FONT style="white-space: nowrap">article&#160;211-2</FONT>
    of the General Regulations (<I>R&#232;glement
    G&#233;n&#233;ral</I>) of the <I>Autorit&#233; des March&#233;s
    Financiers</I>, does not constitute a public offer (<I>appel
    public &#224; l&#146;&#233;pargne</I>).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The shares may be resold directly or indirectly, only in
    compliance with
    <FONT style="white-space: nowrap">articles&#160;L.411-1,</FONT>
    L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French
    <I>Code mon&#233;taire et financier</I>.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Notice to
    Prospective Investors in Hong Kong</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The shares may not be offered or sold in Hong Kong by means of
    any document other than (i)&#160;in circumstances which do not
    constitute an offer to the public within the meaning of the
    Companies Ordinance (Cap. 32, Laws of Hong Kong), or
    (ii)&#160;to &#147;professional investors&#148; within the
    meaning of the Securities and Futures Ordinance (Cap. 571, Laws
    of Hong Kong) and any rules made thereunder, or (iii)&#160;in
    other circumstances which do not result in the document being a
    &#147;prospectus&#148; within the meaning of the Companies
    Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement,
    invitation or document relating to the shares may be issued or
    may be in the possession of any person for the purpose of issue
    (in each case whether in Hong Kong or elsewhere), which is
    directed at, or the contents of which are likely to be accessed
    or read by, the public in Hong Kong (except if permitted to do
    so under the laws of Hong Kong) other than with respect to
    shares which are or are intended to be disposed of only to
    persons outside Hong Kong or only to &#147;professional
    investors&#148; within the meaning of the Securities and Futures
    Ordinance (Cap. 571, Laws of Hong Kong) and any rules made
    thereunder.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Notice to
    Prospective Investors in Japan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The shares offered in this prospectus supplement have not been
    registered under the Securities and Exchange Law of Japan. The
    shares have not been offered or sold and will not be offered or
    sold, directly or indirectly, in Japan or to or for the account
    of any resident of Japan, except (i)&#160;pursuant to an
    exemption from the registration requirements of the Securities
    and Exchange Law and (ii)&#160;in compliance with any other
    applicable requirements of Japanese law.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Notice to
    Prospective Investors in Singapore</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus supplement and the accompanying prospectus have
    not been registered as a prospectus with the Monetary Authority
    of Singapore. Accordingly, this prospectus supplement and the
    accompanying prospectus and any other document or material in
    connection with the offer or sale, or invitation for
    subscription or purchase, of the shares may not be circulated or
    distributed, nor may the shares be offered or sold, or be made
    the subject of an invitation for subscription or purchase,
    whether directly or indirectly, to persons in Singapore other
    than (i)&#160;to an institutional investor under
    Section&#160;274 of the Securities and Futures Act,
    Chapter&#160;289 of Singapore (the &#147;SFA&#148;),
    (ii)&#160;to a relevant person pursuant to Section&#160;275(1),
    or any person pursuant to Section&#160;275(1A), and in
    accordance with the conditions specified in Section&#160;275 of
    the SFA or (iii)&#160;otherwise pursuant to, and in accordance
    with the conditions of, any other applicable provision of the
    SFA, in each case subject to compliance with conditions set
    forth in the SFA.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Where the shares are subscribed or purchased under
    Section&#160;275 of the SFA by a relevant person which is:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (which is not an accredited investor (as defined
    in Section&#160;4A of the SFA)) the sole business of which is to
    hold investments and the entire share capital of which is owned
    by one or more individuals, each of whom is an accredited
    investor;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust (where the trustee is not an accredited investor) whose
    sole purpose is to hold investments and each beneficiary of the
    trust is an individual who is an accredited investor,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    shares, debentures and units of shares and debentures of that
    corporation or the beneficiaries&#146; rights and interest
    (howsoever described) in that trust shall not be transferred
    within six months after that corporation or that trust has
    acquired the shares pursuant to an offer made under
    Section&#160;275 of the SFA except:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to an institutional investor (for corporations, under
    Section&#160;274 of the SFA) or to a relevant person defined in
    Section&#160;275(2) of the SFA, or to any person pursuant to an
    offer that is made on terms that such shares, debentures and
    units of shares and debentures of that corporation or such
    rights and interest in that trust are acquired at a
    consideration of not less than S$200,000 (or its equivalent in a
    foreign currency) for each transaction, whether such amount is
    to be paid for in cash or by exchange of securities or other
    assets, and further for corporations, in accordance with the
    conditions specified in Section&#160;275 of the SFA;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    where no consideration is or will be given for the
    transfer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    where the transfer is by operation of law.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Notice to
    Prospective Investors in Israel</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus supplement and the accompanying prospectus are
    not, and under no circumstances are to be construed as an
    advertisement or a public offering of securities in Israel. Any
    public offer or sale of securities in Israel may be made only in
    accordance with the Israeli Securities Act-1968 (which requires,
    inter alia, the filing of a prospectus in Israel or an exemption
    therefrom).
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358124'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Certain legal matters with respect to the common stock will be
    passed upon for us by Morrison&#160;&#038; Foerster LLP, New
    York, New York. Latham&#160;&#038; Watkins LLP, San&#160;Diego,
    California, is counsel for the underwriters in connection with
    this offering.
</DIV>

<A name='E04358125'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The financial statements and management&#146;s assessment of the
    effectiveness of internal control over financial reporting
    (which is included in Management&#146;s Report on Internal
    Control over Financial Reporting) incorporated in this
    prospectus supplement and the accompanying prospectus by
    reference to the Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2010 have been so
    incorporated in reliance on the reports of Kesselman&#160;&#038;
    Kesselman, independent registered public accounting firm, and a
    member firm of PricewaterhouseCoopers International Limited,
    each member firm of which is a separate legal entity, given on
    the authority of said firm as experts in auditing and accounting.
</DIV>

<A name='E04358126'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND MORE INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus supplement and the accompanying prospectus are
    part of a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    that we filed with the SEC under the Securities Act. This
    prospectus supplement and the accompanying prospectus do not
    contain all of the information included in the registration
    statement. We have omitted certain parts of the registration
    statement in accordance with the rules and regulations of the
    SEC. For further information, we refer you to the registration
    statement, including its exhibits and schedules. Statements
    contained in this prospectus supplement and the accompanying
    prospectus about the provisions or contents of any contract,
    agreement or any other document referred to are not necessarily
    complete. Please refer to the actual exhibit for a more complete
    description of the matters involved.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We file annual, quarterly and current reports, proxy statements
    and other information with the SEC. Our SEC filings, including
    the registration statement and exhibits, are available to the
    public at the SEC&#146;s website at
    <FONT style="white-space: nowrap">http://www.sec.gov.</FONT>
    You may also read, without charge, and copy the documents we
    file, at the SEC&#146;s public reference rooms at
    100&#160;F&#160;Street, N.E., Room&#160;1580,
    Washington,&#160;D.C. 20549. You can request copies of these
    documents by writing to the SEC and paying a fee for the copying
    cost. Please call the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for further information on the public reference rooms. In
    addition, since we are also listed on the Tel Aviv Stock
    Exchange, we submit copies of all our filings with the SEC to
    the Israeli Securities Authority and the Tel Aviv Stock
    Exchange. Such copies can be retrieved electronically through
    the Tel Aviv Stock Exchange&#146;s internet messaging system
    (www.maya.tase.co.il) and through the MAGNA distribution site of
    the Israeli Securities Authority (www.magna.isa.gov.il).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We maintain an Internet site at www.protalix.com. Webcasts of
    presentations we make at certain conferences may also be
    available on our website from time to time. We have not
    incorporated by reference into this prospectus supplement or the
    accompanying prospectus the information on our website, and you
    should not consider any of the information posted on or
    hyper-linked to our website to be a part of this prospectus
    supplement or the accompanying prospectus.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='E04358127'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">INCORPORATION
    OF CERTAIN DOCUMENTS BY REFERENCE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The SEC allows us to &#147;incorporate by reference&#148; the
    information we file with the SEC, which means we can disclose
    important information to you by referring you to those
    documents. The information we incorporate by reference is an
    important part of this prospectus supplement, and certain
    information that we will later file with the SEC will
    automatically update and supersede this information. We
    incorporate by reference the documents listed below as well as
    any future filings made with the SEC under Sections&#160;13(a),
    13(c), 14 or 15(d) of the Exchange Act after the date of this
    prospectus supplement until we sell all of the securities under
    this prospectus supplement, except that we do not incorporate
    any document or portion of a document that is
    &#147;furnished&#148; to the SEC, but not deemed
    &#147;filed.&#148; The following documents filed with the SEC
    are incorporated by reference in this prospectus supplement and
    the accompanying prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2010 filed with the SEC on
    February&#160;23, 2011;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our Current Reports on
    <FONT style="white-space: nowrap">Form&#160;8-K</FONT>
    filed with the SEC on January&#160;19, 2011; January&#160;24,
    2011; January&#160;27, 2011; and February&#160;25, 2011;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the description of our common stock included in our registration
    statement on Form
    <FONT style="white-space: nowrap">8-A12B</FONT> (File
    <FONT style="white-space: nowrap">No.&#160;001-33357)</FONT>
    filed with the SEC on March&#160;9, 2007, including any
    amendment or reports filed for the purpose of updating such
    description.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Copies of these filings are available at no cost on our website,
    www.protalix.com. In addition, you may request a copy of these
    filings and any amendments thereto at no cost, by writing or
    telephoning us. Those copies will not include exhibits to those
    documents unless the exhibits are specifically incorporated by
    reference in the documents or unless you specifically request
    them. You may also request copies of any exhibits to the
    registration statement at no cost. Please direct your request to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Yossi Maimon<BR>
    2 Snunit Street<BR>
    Science Park<BR>
    POB 455<BR>
    Carmiel, Israel 20100<BR>
    +972-4-988-9488
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    S-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>PROSPECTUS</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-size: 18pt; font-family: 'Times New Roman', Times">$150,000,000</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04358bby0435801.gif" alt="(PROTALIX LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 18pt">Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may, from time to time, offer to sell shares of our common
    stock. The aggregate public offering price of the securities
    that we may offer through this prospectus will be up to
    $150,000,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will provide the specific terms of the securities offered by
    us in supplements to this prospectus, which we will deliver
    together with the prospectus at the time of sale. This
    prospectus may not be used to sell securities unless accompanied
    by a prospectus supplement. Please read this prospectus and the
    applicable prospectus supplement carefully before you invest in
    any of our securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may, from time to time, offer and sell these securities
    directly or through one or more underwriters, agents or dealers,
    through underwriting syndicates managed or co-managed by one or
    more underwriters, or directly to purchasers, on or off the NYSE
    Amex at prevailing market prices or at privately negotiated
    prices, on a continuous or delayed basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock is listed on the NYSE Amex under the symbol
    &#147;PLX&#148; and on the Tel Aviv Stock Exchange under the
    symbol &#147;PLX.&#148; On January&#160;6, 2011, the last
    reported sale price of our common stock was $10.46 per share on
    the NYSE Amex and NIS 36.75 per share on the Tel Aviv Stock
    Exchange.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 18%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 12pt">Investing in our securities
    involves risks. Risks associated with an investment in our
    securities will be described in the applicable prospectus
    supplement and certain of our filings with the Securities and
    Exchange Commission, as described under the caption &#147;Risk
    Factors&#148; on page&#160;4.</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 18%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>None of the Securities and Exchange Commission, the Israeli
    Securities Authority or any state securities commission has
    approved or disapproved of these securities or passed upon the
    adequacy or accuracy of this prospectus. Any representation to
    the contrary is a criminal offense.</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The date of this prospectus is January&#160;13, 2011
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="Y04358tocpage"></A>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="97%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358101'>Cautionary Statement Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358102'>About This Prospectus</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358103'>Our Business</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358104'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358105'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358106'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358107'>Securities We May Offer</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358108'>Description of Common Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358109'>Plan of Distribution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358110'>Where You Can Find More Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358111'>Incorporation of Certain Documents by
    Reference</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358112'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04358113'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>No dealer, salesman or other person has been authorized to
    give any information or to make any representations in
    connection with the offer made by this prospectus or any
    prospectus supplement other than those contained in, or
    incorporated by reference in, this prospectus or any prospectus
    supplement, and if given or made, such information or
    representations must not be relied upon as having been
    authorized by us or any underwriter, agent or dealer. We or an
    authorized underwriter, agent or dealer may also furnish you
    with a free writing prospectus relating to the applicable
    securities. This prospectus, any prospectus supplement or any
    free writing prospectus does not constitute an offer to sell or
    a solicitation of any offer to buy any securities in any
    jurisdiction to any person to whom it is unlawful to make an
    offer or solicitation in such jurisdiction. The delivery of this
    prospectus, any prospectus supplement or any free writing
    prospectus at any time does not imply that the information
    contained herein or therein is correct as of any time subsequent
    to their respective dates.</B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='Y04358101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CAUTIONARY
    STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The statements set forth and incorporated by reference in this
    prospectus, which are not historical, constitute &#147;forward
    looking statements&#148; within the meaning of Section&#160;27A
    of the Securities Act of 1933, as amended, and Section&#160;21E
    of the Securities Exchange Act of 1934, as amended, including
    statements regarding the expectations, beliefs, intentions or
    strategies for the future. When used in this prospectus, or in
    any document incorporated by reference in this prospectus, the
    terms &#147;anticipate,&#148; &#147;believe,&#148;
    &#147;estimate,&#148; &#147;expect&#148; and &#147;intend&#148;
    and words or phrases of similar import, as they relate to us, or
    our subsidiaries or our management, are intended to identify
    forward-looking statements. We intend that all forward-looking
    statements be subject to the safe-harbor provisions of the
    Private Securities Litigation Reform Act of 1995.
    Forward-looking statements are subject to many risks and
    uncertainties that could cause our actual results to differ
    materially from any future results expressed or implied by the
    forward-looking statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Examples of the risks and uncertainties include, but are not
    limited to, the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the inherent risks and uncertainties in developing drug
    platforms and products of the type we are developing;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in our preparation and filing of applications for
    regulatory approval;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in the approval or the potential rejection of any
    applications we file with the U.S.&#160;Food and Drug
    Administration, or the FDA, or other regulatory authorities,
    including the New Drug Application (NDA) we have filed with the
    FDA and the Marketing Authorization Application (MAA) we have
    submitted to the European Medicines Agency, or the EMEA, for
    taliglucerase alfa;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any lack of progress of our research and development (including
    the results of clinical trials we are conducting);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtaining on a timely basis sufficient patient enrollment in our
    clinical trials;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the impact of development of competing therapies
    <FONT style="white-space: nowrap">and/or</FONT>
    technologies by other companies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to obtain additional financing required to fund our
    research programs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risk that we will not be able to develop a successful sales
    and marketing organization in a timely manner, if at all;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to establish and maintain strategic license,
    collaboration and distribution arrangements and to manage our
    relationship with Pfizer Inc., Teva Ltd. or with any other
    collaborator, distributor or partner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potential product liability risks, and risks of securing
    adequate levels of product liability and clinical trial
    insurance coverage;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the availability of reimbursement to patients from health care
    payors for any of our product candidates, if approved;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possibility of infringing a third party&#146;s patents or
    other intellectual property rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the uncertainty of obtaining patents covering our products and
    processes and in successfully enforcing our intellectual
    property rights against third parties;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possible disruption of our operations due to terrorist
    activities and armed conflict, including as a result of the
    disruption of the operations of regulatory authorities, our
    subsidiaries, our manufacturing facilities and our customers,
    suppliers, distributors, collaborative partners, licensees and
    clinical trial sites.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, companies in the pharmaceutical and biotechnology
    industries have suffered significant setbacks in advanced or
    late-stage clinical trials, even after obtaining promising
    earlier trial results or preliminary findings for such clinical
    trials. Even if favorable testing data is generated in clinical
    trials of a drug product, the FDA might not accept or approve an
    NDA, and the EMEA may not accept an MAA, filed or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    submitted by a pharmaceutical or biotechnology company for the
    drug product. These and other risks and uncertainties are
    detailed in our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, Section&#160;1A,
    under the heading &#147;Risk Factors,&#148; and described from
    time to time in our future reports to be filed with the
    Securities and Exchange Commission, or SEC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any or all of our forward-looking statements are only
    predictions and reflect our views as of the date they are made
    with respect to future events and financial performance and we
    undertake no obligation to update or revise, nor do we have a
    policy of updating or revising, any forward-looking statement to
    reflect events or circumstances after the date on which the
    statement is made or to reflect the occurrence of unanticipated
    events, except as may be required under applicable law.
</DIV>

<A name='Y04358102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">ABOUT
    THIS PROSPECTUS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus is part of a registration statement that we
    filed with the SEC using a &#147;shelf&#148; registration
    process. Under this shelf registration process, we may sell
    shares of common stock in one or more offerings, up to a total
    dollar amount of $150,000,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus provides you with a general description of the
    securities we may offer under this prospectus. Each time we sell
    securities, we will provide a prospectus supplement that will
    contain specific information about the terms of that offering.
    The prospectus supplement may also add, update or change
    information contained in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The SEC allows us to &#147;incorporate by reference&#148;
    certain information that we file with it, which means that we
    can disclose important information to you by referring you to
    those documents. The information incorporated by reference is
    considered to be part of this prospectus, and information that
    we file later with the SEC will update automatically, supplement
    <FONT style="white-space: nowrap">and/or</FONT>
    supersede this information. Any statement contained in a
    document incorporated or deemed to be incorporated by reference
    in this prospectus shall be deemed to be modified or superseded
    for purposes of this prospectus to the extent that a statement
    contained in this prospectus or in any other document which also
    is or is deemed to be incorporated by reference in this
    prospectus modifies or supersedes such statement. Any such
    statement so modified or superseded shall not be deemed, except
    as so modified or superseded, to constitute a part of this
    prospectus. You should read the detailed information regarding
    our company, our common stock and our financial statements and
    the notes to those statements appearing elsewhere in this
    prospectus or incorporated herein by reference.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You should read both this prospectus and the applicable
    prospectus supplement together with additional information from
    the sources described under the caption &#147;Where You Can Find
    More Information&#148; in this prospectus. You should not assume
    that the information in this prospectus, the prospectus
    supplements, any free writing prospectus or any document
    incorporated by reference is accurate as of any date subsequent
    to their respective dates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You should rely only on the information provided or incorporated
    by reference in this prospectus, any free writing prospectus and
    any prospectus supplement, as applicable. We have not authorized
    anyone to provide you with different information.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    References in this prospectus to &#147;our company,&#148;
    &#147;we,&#148; &#147;our,&#148; and &#147;us&#148; refer to
    Protalix BioTherapeutics, Inc.
</DIV>

<A name='Y04358103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">OUR
    BUSINESS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a biopharmaceutical company focused on the development
    and commercialization of recombinant therapeutic proteins based
    on our proprietary
    ProCellEx<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    protein expression system, or ProCellEx. Using our ProCellEx
    system, we are developing a pipeline of proprietary, biosimilar
    or &#147;generic&#148; versions of recombinant therapeutic
    proteins based on our plant cell-based expression technology
    that target large, established pharmaceutical markets and that
    rely upon known biological mechanisms of action. Our initial
    commercial focus has been on complex therapeutic proteins,
    including proteins for the treatment of genetic disorders, such
    as Gaucher disease and Fabry disease. We believe our ProCellEx
    protein expression system will enable us to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    develop proprietary recombinant proteins that are
    therapeutically equivalent or superior to existing recombinant
    proteins currently marketed for the same indications. Because we
    are primarily targeting biologically equivalent versions of
    highly active, well-tolerated and commercially successful
    therapeutic proteins, we believe our development process is
    associated with relatively less risk compared to other
    biopharmaceutical development processes for completely novel
    therapeutic proteins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our lead product development candidate is taliglucerase alfa for
    the treatment of Gaucher disease, which we are developing using
    our ProCellEx protein expression system. Gaucher disease is a
    rare and serious lysosomal storage disorder with severe and
    debilitating symptoms. Taliglucerase alfa is our proprietary
    recombinant form of glucocerebrosidase (GCD), an enzyme
    naturally found in human cells that is mutated or deficient in
    patients with Gaucher disease. In July 2007, we reached an
    agreement with the U.S.&#160;Food and Drug Administration, or
    the FDA, on the final design of our pivotal phase&#160;III
    clinical trial of taliglucerase alfa, through the FDA&#146;s
    special protocol assessment (SPA) process. The phase&#160;III
    clinical trial was completed in September 2009 and, on
    October&#160;15, 2009, we announced positive top-line results
    from the trial. On December&#160;9, 2009, we filed our New Drug
    Application (NDA) for taliglucerase alfa for the treatment of
    Gaucher disease, and in January 2010 the FDA requested
    additional data regarding the Chemistry, Manufacturing and
    Controls (CMC)&#160;section of the NDA. We provided the
    requested data in April 2010 and in July 2010 we received
    notification from the FDA that it had accepted the filing of the
    NDA and assigned a PDUFA date of February&#160;25, 2011 to
    taliglucerase alfa. In addition, in November 2010 we submitted a
    Marketing Authorization Application to the European Medicines
    Agency, or EMEA, for taliglucerase alfa for the treatment of
    Gaucher disease.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In March 2010, the Israeli Ministry of Health completed a
    successful audit of our manufacturing facilities in Carmiel,
    Israel. The audit was performed as part of the Ministry of
    Health&#146;s evaluation of our manufacturing process for
    taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to our recently completed phase&#160;III clinical
    trial of taliglucerase alfa, during the third quarter of 2008,
    we initiated a double-blind, follow-on extension study as part
    of the trial. We also initiated a home care treatment program
    for patients enrolled in the extension study and in December
    2008, we initiated a nine-month, worldwide, multi-center,
    open-label, switch-over clinical study evaluating the safety and
    efficacy of switching Gaucher patients currently treated under
    the current standard of care to treatment with taliglucerase
    alfa. The current standard of care for Gaucher patients is
    enzyme replacement therapy with
    Cerezyme<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    which is produced by Genzyme Corporation and, until the recent
    approval of
    VPRIV<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    by Shire plc in February 2010, the only approved enzyme
    replacement therapy for Gaucher disease. Enzyme replacement
    therapy is a medical treatment in which recombinant enzymes are
    injected into patients in whom the enzyme is lacking or
    dysfunctional. The switch-over study is not a prerequisite for
    approval of taliglucerase alfa by the FDA. In December 2009 we
    filed a proposed pediatric investigation plan to the Pediatric
    Committee of the EMEA which was approved during the second
    quarter of 2010. In November 2010, we announced positive
    preliminary data from the first 15&#160;patients that completed
    the switch-over clinical study of taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On November&#160;30, 2009, Protalix Ltd. and Pfizer Inc., or
    Pfizer, entered into an exclusive license and supply agreement
    pursuant to which Pfizer was granted an exclusive, worldwide
    license to develop and commercialize taliglucerase alfa. Under
    the terms and conditions of the Pfizer agreement, Protalix Ltd.
    retained the right to commercialize taliglucerase alfa in
    Israel. In connection with the execution of the Pfizer
    agreement, Pfizer made an upfront payment to Protalix Ltd. of
    $60.0&#160;million in connection with the execution of the
    agreement and subsequently paid Protalix Ltd. an additional
    $5.0&#160;million upon our filing of a proposed pediatric
    investigation plan to the Pediatric Committee of the EMEA.
    Protalix Ltd. is also eligible to receive potential milestone
    payments totaling $50.0&#160;million for the successful
    achievement of other developmental milestones and to payments
    equal to 40% of the net profits earned on Pfizer&#146;s sales of
    taliglucerase alfa, if any. Pfizer and Protalix Ltd. have agreed
    to a specific allocation of the responsibilities for the
    continued development efforts for taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In July 2009, following a request by the FDA, we submitted a
    treatment protocol to the FDA in order to address an expected
    shortage of the current enzyme replacement therapy approved for
    Gaucher disease. The treatment protocol was approved by the FDA
    in August 2009. In September 2009, the FDA&#146;s Office of
    Orphan
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Product Development granted taliglucerase alfa Orphan Drug
    Status. In January 2010, the Committee for Orphan Medicinal
    Products (COMP) of the EMEA, after reviewing all relevant
    clinical data, recommended that the European Commission grant
    orphan drug designation to taliglucerase alfa for the treatment
    of Gaucher disease. The Orphan Drug designation in the United
    States for taliglucerase alfa for the treatment of Gaucher
    disease provides special status to taliglucerase alfa provided
    that it meets certain criteria. As a result of the orphan
    designation, we are qualified for the tax credit and marketing
    incentives of the Orphan Drug Act of 1983. A marketing
    application for a prescription drug product that has been
    designated as a drug for a rare disease or condition is not
    subject to a prescription drug user fee unless the application
    includes an indication for other than a rare disease or
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;13, 2010, we announced that the French regulatory
    authority had granted an Autorisation Temporaire
    d&#146;Utilisation (ATU), or Temporary Authorization for Use,
    for taliglucerase alfa for the treatment of Gaucher disease. An
    ATU is the regulatory mechanism used by the French Health
    Products and Safety Agency to make non-approved drugs available
    to patients in France when a genuine public health need exists.
    This ATU allows patients with Gaucher disease in France to
    receive treatment with taliglucerase alfa before marketing
    authorization for the product is granted in the European Union.
    Payment for taliglucerase alfa has been secured through
    government allocations to hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On August&#160;10, 2010, Pfizer entered into a $30&#160;million
    short-term supply agreement with the Ministry of Health of
    Brazil pursuant to which we and Pfizer will provide
    taliglucerase alfa to Gaucher disease patients in such country.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to taliglucerase alfa, we are developing an
    innovative product pipeline using our ProCellEx protein
    expression system. Our product pipeline currently includes,
    among other candidates, therapeutic protein candidates for the
    treatment of Fabry disease, a rare, genetic lysosomal disorder
    in humans, an acetylcholinesterase enzyme-based therapy for
    biodefense, antiTNF, a plant cell expressed recombinant fusion
    protein made from the soluble form of the human TNF receptor
    (TNFR) which is being developed as a treatment of certain immune
    diseases such as rheumatoid arthritis, juvenile idiopathic
    arthritis and others, and additional undisclosed therapeutic
    proteins and intoxication treatments, all of which are currently
    being evaluated in animal studies. In March 2010, we initiated a
    phase I clinical trial of PRX-105, our plant cell expressed
    pegylated recombinant acetylcholinesterase product candidate for
    biodefense indications, which we completed in June 2010. We are
    currently preparing for further efficacy trials in larger
    animals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Except for the license we have granted to Pfizer, we hold the
    worldwide commercialization rights to our proprietary
    development candidates and we intend to establish an internal,
    commercial infrastructure and targeted sales force to market
    taliglucerase alfa in Israel and our other products, if
    approved, in North America, the European Union and in other
    significant markets, including Israel. In addition, we are
    continuously evaluating potential strategic marketing
    partnerships.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock is listed on the NYSE Amex and, since
    September&#160;6, 2010, on the Tel Aviv Stock Exchange, both
    under the symbol &#147;PLX.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    ProCellEx<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    is our trademark. Each of the other trademarks, trade names or
    service marks appearing in this prospectus belongs to its
    respective holder.
</DIV>

<A name='Y04358104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Investing in our securities involves a high degree of risk. You
    should carefully consider the specific risks sets forth under
    the caption &#147;Risk Factors&#148; in the applicable
    prospectus supplement and under the captions &#147;Risk
    Factors&#148; in any of our filings with the SEC, including our
    Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009 before making an
    investment decision. For additional information, please see the
    sources described under the caption &#147;Where You Can Find
    More Information.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='Y04358105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will retain broad discretion over the use of the net proceeds
    of the securities we offer hereby. Unless the applicable
    prospectus supplement states otherwise, the net proceeds from
    the securities we sell will be added to our general corporate
    funds and may be used for research and development expenses,
    clinical trials, establishing an internal sales force,
    acquisitions of new technologies or businesses, and general
    corporate and administrative purposes. Until the net proceeds
    have been used, they will be invested in short-term bank
    deposits or marketable securities. If we elect at the time of
    the issuance of the securities to make different or more
    specific uses of proceeds other than as described in this
    prospectus, the change in use of proceeds will be described in
    the applicable prospectus supplement.
</DIV>

<A name='Y04358106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will set forth in a prospectus supplement the following
    information regarding any material dilution of the equity
    interests of investors purchasing securities in an offering
    under this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the net tangible book value per share of our equity securities
    before and after the offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amount of the increase in such net tangible book value per
    share attributable to the cash payments made by purchasers in
    the offering;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amount of the immediate dilution from the public offering
    price which will be absorbed by such purchasers.
</TD>
</TR>

</TABLE>

<A name='Y04358107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">SECURITIES
    WE MAY OFFER</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Types of
    Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may offer, from time to time, shares of common stock through
    this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will describe in a prospectus supplement, which we will
    deliver with this prospectus at the time of sale, the terms of
    the particular securities that we may offer in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The aggregate initial offering price of all securities sold will
    not exceed $150,000,000. When we sell securities, we will
    determine the amounts of securities we will sell and the prices
    and other terms on which we will sell them. We may sell
    securities to or through underwriters, through agents or dealers
    or directly to purchasers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Additional
    Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will describe in a prospectus supplement, which we will
    deliver with this prospectus, the terms of the securities which
    we may offer in the future. In each prospectus supplement we
    will include the following information:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amount of securities which we propose to sell;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the initial public offering price of the securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the names of the underwriters, agents or dealers, if any,
    through or to which we will sell the securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the compensation, if any, of those underwriters, agents or
    dealers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if applicable, information about any securities exchange or
    automated quotation system on which the securities will be
    listed or traded;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    material U.S.&#160;federal income tax considerations applicable
    to the securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any material risk factors associated with the securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    payment of dividends, if any;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    voting or other rights, if any;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any other material information about the offer and sale of the
    securities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, the prospectus supplement may add, update or change
    the information contained in this prospectus.
</DIV>

<A name='Y04358108'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF COMMON STOCK</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a Florida corporation. The rights of our stockholders are
    governed by the Florida Business Corporation Act, or the FBCA,
    our amended and restated articles of incorporation and our
    amended and restated bylaws. The following summary of the
    material terms, rights and preferences of our capital stock is
    not complete. You should read our amended and restated articles
    of incorporation, which we refer to as our charter, and our
    bylaws, for more complete information before you purchase any of
    our securities. You should read these documents, copies of which
    are available from us upon request at the address set forth
    under the caption &#147;Where You Can Find More
    Information,&#148; in order to more fully understand the terms
    of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>General.</I>&#160;&#160;Our charter provides that we may
    issue up to 150,000,000&#160;shares of common stock, par value
    $0.001 per share, and 100,000,000&#160;shares of preferred
    stock, par value $0.0001 per share, all of which preferred stock
    are undesignated. As of January 4<B><I>, </I></B>2011,
    81,269,472&#160;shares of our common stock were issued and
    outstanding and no shares of preferred stock were issued and
    outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Holders of common stock are entitled to one vote for each share
    held on all matters submitted to a vote of stockholders and do
    not have cumulative voting rights. Accordingly, holders of a
    majority of the shares of common stock entitled to vote in any
    election of directors may elect all of the directors standing
    for election. Holders of common stock are entitled to receive
    dividends when, as and if declared by our board of directors out
    of funds legally available therefor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the event of our liquidation, dissolution or winding up,
    after payment of all of our debts and liabilities, the holders
    of our common stock are entitled to share ratably in all
    remaining assets available for distribution after the payment of
    debts and liabilities and after provision has been made for each
    class of stock, if any, having preferences over our common
    stock. Holders of our common stock, as such, have no preemptive
    or other rights and there are no redemption provisions
    applicable to our common stock. All of our outstanding shares of
    common stock are fully paid and nonassessable. The rights,
    preferences and privileges of holders of common stock are
    subject to, and may be adversely affected by, the rights of the
    holders of shares of any series of preferred stock that we may
    designate and issue in the future. In accordance with the rules
    of the Tel&#160;Aviv Stock Exchange, other than stock options
    under our 2006 Stock Option Plan, we may not issue any
    securities of any class or series different than the common
    stock that is listed on the Tel Aviv Stock Exchange for the
    <FONT style="white-space: nowrap">12-month</FONT>
    period immediately succeeding our initial listing, which
    occurred on September&#160;6, 2010. Subsequent to such
    <FONT style="white-space: nowrap">12-month</FONT>
    period, the rules of the Tel Aviv Stock Exchange allow us to
    issue securities with preferential rights relating to dividends,
    but such other securities may not include voting rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Dividend Policy.</I>&#160;&#160;We have never declared or
    paid any cash dividends on our capital stock. We currently
    intend to retain any future earnings to finance the growth and
    development of our business and therefore do not anticipate
    paying any cash dividends in the foreseeable future. Any future
    determination to pay cash dividends will be at the discretion of
    our board of directors and will depend upon our financial
    condition, operating results, capital requirements, covenants in
    our debt instruments (if any), and such other factors as our
    board of directors deems relevant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Transfer Agent and Registrar.</I>&#160;&#160;The transfer
    agent and registrar of our common stock is American Stock
    Transfer&#160;&#038; Trust&#160;Company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Options</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of January&#160;4, 2011, options to purchase
    7,785,671&#160;shares of our common stock at a weighted average
    exercise price equal to $3.72 per share were outstanding.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Florida
    Anti-Takeover Law Governance and Certain Charter
    Provisions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have elected not to be subject to the provisions of
    Sections&#160;607.0901 and 607.0902 of the FBCA.
    Section&#160;607.0902 of the FBCA prohibits the voting of shares
    in a publicly-held Florida corporation that are acquired in a
    &#147;control share acquisition&#148; unless the holders of a
    majority of the corporation&#146;s voting shares (exclusive of
    shares held by officers of the corporation, inside directors or
    the acquiring party) approve the granting of voting rights as to
    the shares acquired in the control share acquisition or unless
    the acquisition is approved by the corporation&#146;s Board of
    Directors. A &#147;control share acquisition&#148; is defined as
    an acquisition that immediately thereafter entitles the
    acquiring party to vote in the election of directors within each
    of the following ranges of voting power: (i)&#160;one-fifth or
    more but less than one-third of all voting power;
    (ii)&#160;one-third or more but less than a majority of all
    voting power; and (iii)&#160;more than a majority of all voting
    power.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Sections&#160;607.0901 of the FBCA contains an &#147;affiliated
    transaction&#148; provision that prohibits a publicly-held
    Florida corporation from engaging in a broad range of business
    combinations or other extraordinary corporate transactions with
    an &#147;interested shareholder&#148; unless, among others:
    (i)&#160;the transaction is approved by a majority of
    disinterested directors before the person becomes an interested
    shareholder; (ii)&#160;the interested shareholder has owned at
    least 80% of the corporation&#146;s outstanding voting shares
    for at least five years; or (iii)&#160;the transaction is
    approved by the holders of two-thirds of the corporation&#146;s
    voting shares other than those owned by the interested
    shareholder. An interested shareholder is defined as a person
    who together with affiliates and associates beneficially owns
    more than 10% of the corporation&#146;s outstanding voting
    shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NYSE Amex
    and Tel Aviv Stock Exchange</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock is listed on both the NYSE Amex and the Tel
    Aviv Stock Exchange under the symbol &#147;PLX.&#148;
</DIV>

<A name='Y04358109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PLAN OF
    DISTRIBUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may sell the securities from time to time pursuant to
    underwritten public offerings, negotiated transactions, at the
    market offerings, block trades or a combination of these
    methods. We may sell the securities to or through underwriters
    or dealers, through agents, or directly to one or more
    purchasers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may distribute securities from time to time in one or more
    transactions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at a fixed price or prices, which may be changed;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at market prices prevailing at the time of sale;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at prices related to such prevailing market prices;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at negotiated prices.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Unless stated otherwise in the applicable prospectus supplement,
    the obligations of any underwriter to purchase securities will
    be subject to certain conditions, and the underwriter will be
    obligated to purchase all of the applicable securities if any
    are purchased. If a dealer is used in a sale, we may sell the
    securities to the dealer as principal. The dealer may then
    resell the securities to the public at varying prices to be
    determined by the dealer at the time of resale.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We or our agents may solicit offers to purchase securities from
    time to time. Unless stated otherwise in the applicable
    prospectus supplement, any agent will be acting on a best
    efforts basis for the period of its appointment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with the sale of securities, underwriters or
    agents may receive compensation (in the form of discounts,
    concessions or commissions) from us or from purchasers of
    securities for whom they may act as agents. Underwriters may
    sell securities to or through dealers, and such dealers may
    receive compensation in the form of discounts, concessions or
    commissions from the underwriters
    <FONT style="white-space: nowrap">and/or</FONT>
    commissions from the purchasers for whom they may act as agents.
    Underwriters, dealers and agents that participate in the
    distribution of securities may be deemed to be underwriters, as
    that term is defined in the Securities Act, and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    any discounts or commissions received by them from us and any
    profits on the resale of the securities by them may be deemed to
    be underwriting discounts and commissions under the Securities
    Act. We will identify any such underwriter or agent, and we will
    describe any compensation paid to them, in the related
    prospectus supplement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Underwriters, dealers and agents may be entitled under
    agreements with us to indemnification against and contribution
    toward certain civil liabilities, including liabilities under
    the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If stated in the applicable prospectus supplement, we will
    authorize agents and underwriters to solicit offers by certain
    specified institutions or other persons to purchase securities
    at the public offering price set forth in the prospectus
    supplement under delayed delivery contracts providing for
    payment and delivery on a specified date in the future.
    Institutions with whom these contracts may be made include
    commercial and savings banks, insurance companies, pension
    funds, investment companies, educational and charitable
    institutions, and other institutions, but shall in all cases be
    subject to our approval. These contracts will be subject only to
    those conditions set forth in the applicable prospectus
    supplement and the applicable prospectus supplement will set
    forth the commission payable for solicitation of these
    contracts. The obligations of any purchaser under any such
    contract will be subject to the condition that the purchase of
    the securities shall not be prohibited at the time of delivery
    under the laws of the jurisdiction to which the purchaser is
    subject. The underwriters and other agents will not have any
    responsibility in respect of the validity or performance of
    these contracts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The securities may or may not be listed on a national securities
    exchange or traded in the over-the-counter market, as set forth
    in the applicable prospectus supplement. No assurance can be
    given as to the liquidity of the trading market for any of our
    securities. Any underwriter may make a market in these
    securities. However, no underwriter will be obligated to do so,
    and any underwriter may discontinue any market making at any
    time, without prior notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If underwriters or dealers are used in the sale, until the
    distribution of the securities is completed, SEC rules may limit
    the ability of any underwriters and selling group members to bid
    for and purchase the securities. As an exception to these rules,
    representatives of any underwriters are permitted to engage in
    certain transactions that stabilize the price of the securities.
    These transactions may consist of bids or purchases for the
    purpose of pegging, fixing or maintaining the price of the
    securities. If the underwriters create a short position in the
    applicable securities in connection with any offering (in other
    words, if they sell more securities than are set forth on the
    cover page of the applicable prospectus supplement) the
    representatives of the underwriters may reduce that short
    position by purchasing securities in the open market. The
    representatives of the underwriters may also elect to reduce any
    short position by exercising all or part of any over-allotment
    option we may grant to the underwriters, as described in the
    prospectus supplement. The representatives of the underwriters
    may also impose a penalty bid on certain underwriters and
    selling group members. This means that if the representatives
    purchase securities in the open market to reduce the
    underwriters&#146; short position or to stabilize the price of
    the securities, they may reclaim the amount of the selling
    concession from the underwriters and selling group members who
    sold those shares as part of the offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In general, purchases of a security for the purpose of
    stabilization or to reduce a short position could cause the
    price of the security to be higher than it might be in the
    absence of those purchases. The imposition of a penalty bid
    might also have an effect on the price of the securities to the
    extent that it discourages resales of the securities. The
    transactions described above may have the effect of causing the
    price of the securities to be higher than it would otherwise be.
    If commenced, the representatives of the underwriters may
    discontinue any of the transactions at any time. In addition,
    the representatives of any underwriters may determine not to
    engage in those transactions or that those transactions, once
    commenced, may be discontinued without notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Certain of the underwriters or agents and their associates may
    engage in transactions with and perform services for us or our
    affiliates in the ordinary course of their respective businesses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In no event will the commission or discount received by any
    Financial Industry Regulatory Authority, or FINRA, member or
    independent broker-dealer participating in a distribution of
    securities exceed 8% of the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    aggregate principal amount of the offering of securities in
    which that FINRA member or independent broker-dealer
    participates.
</DIV>

<A name='Y04358110'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND MORE INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus is part of a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    that we filed with the SEC under the Securities Act. You should
    rely only on the information contained in this prospectus or
    incorporated by reference in this prospectus. We have not
    authorized anyone else to provide you with different
    information. You should not assume that the information in this
    prospectus is accurate as of any date other than the date on the
    front cover of this prospectus, regardless of the time of
    delivery of this prospectus or any sale of securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We file annual, quarterly and current reports, proxy statements
    and other information with the SEC. Our SEC filings, including
    the registration statement and exhibits, are available to the
    public at the SEC&#146;s website at
    <FONT style="white-space: nowrap">http://www.sec.gov.</FONT>
    You may also read, without charge, and copy the documents we
    file, at the SEC&#146;s public reference rooms at
    100&#160;F&#160;Street, N.E., Room&#160;1580,
    Washington,&#160;D.C. 20549. You can request copies of these
    documents by writing to the SEC and paying a fee for the copying
    cost. Please call the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for further information on the public reference rooms. In
    addition, since we are also listed on the Tel Aviv Stock
    Exchange, we submit copies of all our filings with the SEC to
    the Israeli Securities Authority and the Tel Aviv Stock
    Exchange. Such copies can be retrieved electronically through
    the Tel Aviv Stock Exchange&#146;s internet messaging system
    (www.maya.tase.co.il) and through the MAGNA distribution site of
    the Israeli Securities Authority (www.magna.isa.gov.il).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We maintain an Internet site at www.protalix.com. Webcasts of
    presentations we make at certain conferences may also be
    available on our website from time to time. We have not
    incorporated by reference into this prospectus the information
    on our website, and you should not consider it to be a part of
    this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This prospectus does not contain all of the information included
    in the registration statement. We have omitted certain parts of
    the registration statement in accordance with the rules and
    regulations of the SEC. For further information, we refer you to
    the registration statement, including its exhibits and
    schedules, which may be found at the SEC&#146;s website at
    http://www.sec.gov. Statements contained in this prospectus and
    any accompanying prospectus supplement about the provisions or
    contents of any contract, agreement or any other document
    referred to are not necessarily complete. Please refer to the
    actual exhibit for a more complete description of the matters
    involved.
</DIV>

<A name='Y04358111'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">INCORPORATION
    OF CERTAIN DOCUMENTS BY REFERENCE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The SEC allows us to &#147;incorporate by reference&#148; the
    information we file with the SEC, which means we can disclose
    important information to you by referring you to those
    documents. The information we incorporate by reference is an
    important part of this prospectus, and certain information that
    we will later file with the SEC will automatically update and
    supersede this information. We incorporate by reference the
    documents listed below as well as any future filings made with
    the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the
    Exchange Act from the date of the initial registration statement
    and prior to the effectiveness of this registration statement,
    and any filings made after the date of this prospectus until we
    sell all of the securities under this prospectus, except that we
    do not incorporate any document or portion of a document that is
    &#147;furnished&#148; to the SEC, but not deemed
    &#147;filed.&#148; The following documents filed with the SEC
    are incorporated by reference in this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our Quarterly Report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarters ended March&#160;31, 2010; June&#160;30, 2010;
    and September&#160;30, 2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our Current Reports on
    <FONT style="white-space: nowrap">Form&#160;8-K</FONT>
    filed with the SEC on January&#160;14, 2010; February&#160;2,
    2010; February&#160;5, 2010; February&#160;11, 2010;
    March&#160;3, 2010; March&#160;9, 2010; March&#160;17, 2010;
    April&#160;27, 2010; May&#160;18, 2010; June&#160;8, 2010;
    July&#160;12, 2010; July&#160;13, 2010, August&#160;16, 2010,
    August&#160;30, 2010;
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="2%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    September&#160;7, 2010; September&#160;13, 2010;
    October&#160;25, 2010; November&#160;2, 2010; November&#160;10,
    2010; and November&#160;29, 2010;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our definitive Proxy Statement for our Annual Meeting of
    Shareholders held on November&#160;7, 2010;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the description of our common stock included in our
    <FONT style="white-space: nowrap">Form&#160;8-A</FONT>
    filed with the SEC on March&#160;9, 2007.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Copies of these filings are available at no cost on our website,
    www.protalix.com. In addition, you may request a copy of these
    filings and any amendments thereto at no cost, by writing or
    telephoning us. Those copies will not include exhibits to those
    documents unless the exhibits are specifically incorporated by
    reference in the documents or unless you specifically request
    them. You may also request copies of any exhibits to the
    registration statement at no cost. Please direct your request to:
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Yossi
    Maimon<BR>
    2 Snunit Street<BR>
    Science Park<BR>
    POB 455<BR>
    Carmiel, Israel 20100<BR>
    +972-4-988-9488</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    You should rely only on the information in this prospectus, any
    prospectus supplement, any applicable free writing prospectus
    and the documents that are incorporated by reference. We have
    not authorized anyone else to provide you with different
    information. We are not offering these securities in any state
    where the offering is prohibited by law. You should not assume
    that the information in this prospectus, any prospectus
    supplement, any applicable free writing prospectus or any
    incorporated document is accurate as of any date other than the
    date of the document.
</DIV>

<A name='Y04358112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The validity of the issuance of the shares of common stock
    offered hereby will be passed upon for us by
    Morrison&#160;&#038; Foerster LLP, New York, New York.
</DIV>

<A name='Y04358113'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The financial statements and management&#146;s assessment of the
    effectiveness of internal control over financial reporting
    (which is included in Management&#146;s Report on Internal
    Control over Financial Reporting) incorporated in this
    Prospectus by reference to the Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009 have been so
    incorporated in reliance on the reports of Kesselman&#160;&#038;
    Kesselman, independent registered public accounting firm, and a
    member of PricewaterhouseCoopers International Limited, each
    member firm of which is a separate legal entity, given on the
    authority of said firm as experts in auditing and accounting.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#E04358tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 18pt">4,000,000&#160;Shares</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04358bbe0435801.gif" alt="(PROTALIX LOGO)"><B><FONT style="font-size: 18pt">
    </FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 18pt">Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 10%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 27pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>PROSPECTUS SUPPLEMENT</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>March&#160;17, 2011</B>
</DIV>

<DIV style="margin-top: 27pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 10%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Joint
    Book-Running Managers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 22pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Citi<BR>
    Barclays Capital</FONT></B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y04358bbe0435801.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04358bbe0435801.gif
M1TE&.#EA3@%E`,0?`)J:FLW-S4)"0O/S\[2TM.;FYH&!@=K:VEM;6TY.3G1T
M=(Z.CF"OIL#`P*#/RA"&>?#W]S"6B]#GY:>GIX"_N$">E%"FG<#?W)#'P>#O
M[B".@K#7TVAH:`!^<#4U-?___R'Y!`$``!\`+`````!.`64```7_X">.9&F>
M:*JN;'L6A(%X=%US"S&X?.__P*!P2"RJ`LBD<IDL!`O,Z-+(&A!FMJS6HR#X
M!M*P.+#C095.ZD%Y,)Z1[1*&0J]C4I>Z7D+E0?1U#A];A%D(!CH\`(6,'AR(
M97T#``*-C`(`D2L!EITU`3T)AGT<-AQ&BS<F$@\=KJ\,*!`1KZ\/$'TLL[6N
M#WR>C`9I*ZG`6PJ@J)7&A`)>+)S,C,DMT5G41*6J1<6.)Q*\KK$GN[P1N+DI
M%N&^(M*$"YHGW>\WPT`'6(4<'```"_P:<;AWPEJ]:SP4;#%`11N-4]Q,H7`0
MKL,X$^5JG4MW@@$[/NX.&HJ#@IY(`0V"_Q`HA&`"21,'`.C+@O*(2"W85!0H
M1#"(0V\1MYV@&.YB"0BMS*'C*,(CKW8C;"3P1[4J50,<EFD1\+($/:M@`00L
M]*R'`4+">!PXNZ6LB0)AJ_Z<&M=?3Q0+"@$P\A,BD6Y^AU84]"VIQJ7IG/+:
M4$*BB[5;$L@;08]'``-:;;AEP39+VA\%?M9@"`2PD0&9:?)U_)?UQ,$H6(7;
MF!AV8Z$N"BC,HJ!DEB^4:'9-T;F&@)P_"*3VL/>'Z2(K;=#;#*0O*M>OPQ%>
M9?A5A-K:3V!W,0'GO-\_#HBR@:!%7D.3\<VD09W%<R+K:23XD-]#^VSCE1:@
M"43QLET)LO%B%/\1%-AFPH#VC6)"94`4D%I])#2@!6E4##"?!\,1`Z%E64SP
M072?`(B;$/>MH%@M!Y*08"T+!E$@C"F,N()HPU$(A$$>[)>"A9YQY&$6DO70
M8A"[T2#`#JC9P*%/.KJPI`HOOA+C".`41<2-6JI090I`+C`A>D$4YP%R(S1)
M`P+Q%3%`?\PI.:9.18J@YET\6!?40SUDZ<H%V2DH!)BNW"'FBC[,%)@(/E:8
MA9D%T<2G$0=H<>F9C/I`SS`[23>$GZUUBN5'A=((!*(6L7"G;S9P6@,1;OYG
M@F@I,459GBU<Z4-FC_[TI!"D#N&KBZ@*YF4/K-8HGJDN`"DK#424%ZO_"4`^
MJBN=FY)PK`LHTI#K".%Z@&$+Q;+X*@F"0D5@18JVT*P+ZV*+YJ[7"@%D3VZ"
MJ&L)Y5(:(;0MS"1D"?T=_$.Z07R[0@7)OAL>"S/"PD.])4CKU;T_(D3"`%EH
M^V]_`EB)\0A`FCCMFE02K,C)'V1D"T@2&[A"Q>+T`+,(&N:+[ZQ#`)E3N>/^
M.X*U*0X,:)HV#/L6;RTO7:K4/\C<2P8H"-K!EEQVE[/.+J_PGI,K$P%D5VZ6
M;'0)((NJ-%"@\6K"GM7M[*W=5G=`FPE:<XVSWHBU8'=_VD8*!-+4(BSEVK>.
MZ;`*GY(Y:=UA]VIWS+0HE;6#(OR]]\65HY!R_]FCLL=V%N?J:CBL5/<`[`HD
MQZD"PP*&KD+>G[-;$:&=>PTX$##/F45/J_<0ZF@99Q&BT?N^+3(+1*]0;NHH
MT.[<Y2)`H,%L@8_0+A_:<Q\$S&J*7'Q"611](L>,?Y"I#6QN;#L)!E>1F<(N
M6.\I]KV+WQ$[%\C<882`L0&HB66D`T*Y\/>!;JBM?23P&.0P-CK.2#!__'M<
M#SS7/1%`K"*:(^#\/A"`#PE,?D!+SX6F];RU79!U<..!FF1'@N/1H#<]T)^=
M1G@SWUE`%@($X0.P-H0[P>!#_HG3^5;0@-38ZFX\-,(+SS-"&WI@2CL:7@XS
MR#\9^<Y9F`-A!]PE0O\G\>.,:$3C<FH`IQ0L$06ZV4J(NO%$"`X"?L[;GPV6
M=X*>U>"$+-#ARZ+8PV5A)(@SD^)-;D##-]:0`/VJ`88<R10KQ@^*K6/!ZT+1
M-!J60)`F(Z0*/)<"1+HB=^-;I`!4-D&?P04`6%$C(\X%)$]RI'DBFM_T]"C)
M/G%1E+'Q'2J;(L9A^N`F4[%E`SD6248D@(_NF^+:$.<!R\UO)L<9`Q/\J!]?
M`O-G,2P"4OS'-S&>LH-@8P8"%```:"90!,+K1#Q<Y38[NJF%F`RG319I'G3]
M,I-"P!TZM49.X+%1#.Y\6S5+\+Y"3*5;(_A)'1F7&4#"$)\E."`_<1C(?^K_
M,PAY&^+FPD$!8:)3<-_,90I)0$W_`(``$"T!-6-*A>CEL056Y&<-8@I*:P*T
M:J8DH^["P\%4_I0*Y^M7DN*V.`@**Y1'1:%.;6#1$_3TID,(*<U*T+>N&?*8
M*6WE2C]&)X[Z0%C*+`*0L.C&.]VO+G"M2NPZ&E8-KD"KJ0J3%[\*NJC^*7$G
M:&@-6-F#<K&5*3R"ZD=-L$MCH8ZN?E4L1ED0U*V2@%5^^^(/N@C#A:*@I9=4
M`9T22@1N+I:*D?W`4XG0MAHPL'%UM=OW\NH*KHE@`Q4!8X["VE:?G:!?3BLL
M?/X5)3Q*E@6"K5,1U!1:U7ITLBF8K;(,I8)Y]?6T_]?QK0GB&471')8*\_GN
M12UH`YJN(+EFM>IS@]#5Z:J*!=9%:6K5I5V8:*$YQDN->(>@IN#Z%+L?:"T-
M]GM6+:;@JBH%\$AMYEZ+N8!5%*`7;SO;`M`F9T/I.&!S69A@?]5T<@=>KP_:
M:X(+Y-8'F)6O@AU;7_5V\@<')#`/!B`:Y>[0KX1+QURK)V(>D!A!FOU!BE?`
M6=0"=@7%[:X6$&!>%*@'P]<C6&/[,)T0QW9^0^8.7WO0H(GM=KX-8Y_DLH#?
M&7\($T$8P-B:&N6HSL5(2+(RF,6Z8A%D&<BS(<*/'S1A(WOVOS38\'8UFH!$
MN&`2:Y1Q;X^:W#+W@;D\OO_R?%D5+SR'<`A[CF"?W^G/IC5Y!&MNF@'4QS9(
MDH7%1YTA4Y+[/`33&;KQM?0`C:`UQCQKSFT^<@N2_*8@!&"-;#2`512`1->2
M]M4H$/`5_R6:NTA4FU*XAP9C38(,F#07TKT-KGFIZVIHH:J[#K5('!UF4T5.
M5X9U\4W*_#AJCT"@',EV5#8MU3\/T@:D-H-&C?&9OSXOQT;;,0EJ_`YVC\C$
M6\Z>*8U9A'4\Q;)%YK0WC?/I$A1@`<!V*``JCFS&IF]M]""L"`@N#8-#ZV]@
MS)L&3BK.RFIZVS?N]J&=:(0``.02_3@VMT7VYK4IFX$D9X;)?XIR($9,5WB%
M%%7_J&<VJP@A)E;1>0O6T`"J(('C/0A`5>IC%4%#QRH$(4!<Q^X/;&A]Z2BP
M0`76SO8?HH`";(^[99&N]KA7P.UVS+O>]\[WOOO][X`/O.`'3_C"&_[PB$^\
MXA?/^,8[_O&0C[SD)T_YREO^\IC/O.8WS_G.>_[SH`^]Z$>_B3`H$PQ(@.`9
M^+AZTKL>'U=/P1H"@/5<-"(!"]B4-2"8BA;V_O7`]R:Y(TJ#X>O=$\8GX5C_
M]7M803?XP-=&\J4?>#.F$<KVDCE3FD_%YT/?]=2/=/+M"%"X:*92VN<(]SGE
M_>^//OPN'C\$&;V,!Y)@]^U;O_S:[_[0PQ^V\M<^484T_Z2&>EX7%+X'<_W7
M>?_'4+$'>'ZU#."6=_H'1?RW@)[7@(GG5]J@+0:X:PT`$&?43BOP!I?Q)DL0
M"=P7@FA$@D!0=6?$3J3U@3P#$-03$PIP1@8P`??0>@Y(>S4T`3G(#SLH=8\4
M2X_`@U/W@"4(!S6D!%A@`%,P`K,'458@@OP``/DF.@J@%0D@A?.&41V8??:V
M7<$1&>=B$EM`#;\7`'3B6@>(:(10:)LP*PV0'\E'`&]X`W%0@>$7`$&'`%OH
M9,WT$,VE@=V73X4P<,6G$_OF`9A`0S2V#Z`0@0-&ABK01):``'/4"6SX$.6R
M!1.8(1EG#V.V)F066,66BG[8B/_BM@4<H$RO^&VSTX@#$QAJJ`6,:&,KTPP8
M<B0WY`\+H`^G,("]E#SI%RZXEP0-@!G&,1P$@$;K(0!I1!*IX(4+D`312%72
M(Q4`P(S.Z"3+8PWY08VDIHE.,FK:Z";"EDG2UQD"H(Y(8&K/J`*36`-=L([L
M$2>(R'XD$(UGM`P)D$:[.'P&Q![?F`0+T!^']1Y,9G%G48RG=0#U-QGXYW%.
M(G+P-#9<T4H)6$_WIQ6#B"()D&^30''HYUH80I$UD`DOX!!8H"W:H!7S]!9-
MXE^?9(IOX1"M9HNYU$+]Z%R\.`*=D0#QHQPM:0*5L%38LA<`=8(UD&\720(-
MQ8E'L`S_;>1\B^8!&DF%`NED;$1#O]9K9)A$R59_S54^L'6,*8`BSU,,!#8V
MPQ>4%FAET^>3/V,`-%0`^F!V>(D"UL<!Q88A4SD"6"``$&4-R5>!/X-1*))O
M6)"5^\259(B8*3`VI%4<,GE^+(`TU'$\BM89/4&7^`*4?UF0%H>/./65*'.:
M?+:)?%*8'^!'@R@_.%F:BU:;(K`>%N5'Q_8>]B<"UC"!K16`(Y`?FWE#WL1`
M;/%:*+`>;$6:D')40=F`S9E6?E06[R-CQE`?LKD;WE=<DW14U^@>F;0;B@9/
M;"F<-<!'UG*;;<DH#F%>#?42K<5TY%(#\B"=RW1:U8F7]UD$_^M!/2C(!!,0
MCO2!B=J&GT2IG(FHE=!#-MJFFQEUB?>W?+N8GB.P#,F97BR`!67F1[\B+CDY
ME!`:?W:9(?I9!$BC`)<25=V0$X794$W6,\&)FR<ZF<BX)M"FD&39FNGW`<O`
MH`VJ3]K0E2KP'KA8H#U:0G_)GXPY<JXII;P8I3!F`UWP+(ZY(H4IFW6H?59J
MI1>J:T#R#CNZ*`@T2,EY@")@+8'QB)Z07E!*G5,JE&6V&Z/H`^CH)+FG:9,E
MFF-J;UZJHP]:J(0*I")QIE_&IOVYICX0#8$1=)X0+'5:E^*7HL1GHD-@!73B
MDG<T60WE%EV*H8>Z?[T%7:/Z$&FTJO^LR@^*"IB!ID>.V@-N2@)L08VMFJO\
M`$ASZI]U^G]XRA10^28[D%I)B:@[FE8B$!TW.IVG):;(&JC*6JI*F:!FX8XT
M@*272370*GS69)J:2J4F=X%F,#82"5W'RI[=MI[DY:'.^I&HNGQ167.D*@+H
M.:)&ZJ`\`*(J2@/3F@+!2E[@>I>\Z$?_Z@,LB8H*=CRBNGS@.6/LBJ.&>HHF
M\+"Y<49=,:AMZB3*ZI9K:5[68)\1VY9GY(\?2J?A:J<?DZ[H1@-*JC0O(9O6
M0*$B`)Q*1)ZI)9LHXG6WJJ!G6:F*@ZWZ2E?,R;&[!IT8Z0&>=#P#BZE%"I\I
M2:2?ZE?%A3__7CJ3"84BBXFS*^:EAPE1***1&NNL::H"FKF6YE)A$7L\[CHW
M._4T0-LD37NI-<1&1_NC$C:&0Z(/CN:E#=61\8FW)CNQHH.A#?5,F8B5*8ED
MTZB;:EFB(\M2YC8:--09QH>U@8NR!$MNQ1"+]J@/]KDI/?.R;]&,6C%1@XHB
MJW0":E:/I_JZT$"JJMN5K>LD=S&V(I"P'E"3&:,/,0E;6N&B+]`DDKF61ED0
M#M&VRN<D;$(/<XNB%:N2*("4UMJ:_4:5RU"FC%"\ZEJ&^6D<"]``\U@<@`N[
MA+NXT]LTX8L$0M@TXUBOV(NE$Y`$,J$9K<@<Q:$`\XL$`%`KDBA1_PFI=3.A
M`#2$.!RPOUJ7'Z0+O0S\,<6!>^(;`"'8']1A#0@0P#:W#+T!#'J)OJ*SAR%C
M2V&:L_"[I_L@.[@[`J%A"<[0J`#8GXU`P(!&",89BEI``)#JM"_<6<V0;RN\
MO<7:"`C0IX4;I`%VADO&H"/<M?![Q,`FB%_JO6VYBI]QO\UQ`(7(!6Q:`(]X
MO>=%<L>;PW3;P&^!H#3AJ2C0`,V$9L(9!H>6!-'2O[OJ$L;CA'!DQT@&Q]4@
MQSB@A%6@Q\8S`5BHA9K@@ZBIPF(W@C"59HF<A8;F`P4@R/P@@R.`>GQ4A;+'
MA"DP`%4WA,(6AU5G=1BX@/PYRJ9\RKI2RB:HO,JL7#HIV\JP',L+`[2R7,NV
53,:WG,NZ?,B[W,N[K,J^7`0A```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y04358bby0435801.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04358bby0435801.gif
M1TE&.#EA3@%E`,0?`)J:FLW-S4)"0O/S\[2TM.;FYH&!@=K:VEM;6TY.3G1T
M=(Z.CF"OIL#`P*#/RA"&>?#W]S"6B]#GY:>GIX"_N$">E%"FG<#?W)#'P>#O
M[B".@K#7TVAH:`!^<#4U-?___R'Y!`$``!\`+`````!.`64```7_X">.9&F>
M:*JN;'L6A(%X=%US"S&X?.__P*!P2"RJ`LBD<IDL!`O,Z-+(&A!FMJS6HR#X
M!M*P.+#C095.ZD%Y,)Z1[1*&0J]C4I>Z7D+E0?1U#A];A%D(!CH\`(6,'AR(
M97T#``*-C`(`D2L!EITU`3T)AGT<-AQ&BS<F$@\=KJ\,*!`1KZ\/$'TLL[6N
M#WR>C`9I*ZG`6PJ@J)7&A`)>+)S,C,DMT5G41*6J1<6.)Q*\KK$GN[P1N+DI
M%N&^(M*$"YHGW>\WPT`'6(4<'```"_P:<;AWPEJ]:SP4;#%`11N-4]Q,H7`0
MKL,X$^5JG4MW@@$[/NX.&HJ#@IY(`0V"_Q`HA&`"21,'`.C+@O*(2"W85!0H
M1#"(0V\1MYV@&.YB"0BMS*'C*,(CKW8C;"3P1[4J50,<EFD1\+($/:M@`00L
M]*R'`4+">!PXNZ6LB0)AJ_Z<&M=?3Q0+"@$P\A,BD6Y^AU84]"VIQJ7IG/+:
M4$*BB[5;$L@;08]'``-:;;AEP39+VA\%?M9@"`2PD0&9:?)U_)?UQ,$H6(7;
MF!AV8Z$N"BC,HJ!DEB^4:'9-T;F&@)P_"*3VL/>'Z2(K;=#;#*0O*M>OPQ%>
M9?A5A-K:3V!W,0'GO-\_#HBR@:!%7D.3\<VD09W%<R+K:23XD-]#^VSCE1:@
M"43QLET)LO%B%/\1%-AFPH#VC6)"94`4D%I])#2@!6E4##"?!\,1`Z%E64SP
M072?`(B;$/>MH%@M!Y*08"T+!E$@C"F,N()HPU$(A$$>[)>"A9YQY&$6DO70
M8A"[T2#`#JC9P*%/.KJPI`HOOA+C".`41<2-6JI090I`+C`A>D$4YP%R(S1)
M`P+Q%3%`?\PI.:9.18J@YET\6!?40SUDZ<H%V2DH!)BNW"'FBC[,%)@(/E:8
MA9D%T<2G$0=H<>F9C/I`SS`[23>$GZUUBN5'A=((!*(6L7"G;S9P6@,1;OYG
M@F@I,459GBU<Z4-FC_[TI!"D#N&KBZ@*YF4/K-8HGJDN`"DK#424%ZO_"4`^
MJBN=FY)PK`LHTI#K".%Z@&$+Q;+X*@F"0D5@18JVT*P+ZV*+YJ[7"@%D3VZ"
MJ&L)Y5(:(;0MS"1D"?T=_$.Z07R[0@7)OAL>"S/"PD.])4CKU;T_(D3"`%EH
M^V]_`EB)\0A`FCCMFE02K,C)'V1D"T@2&[A"Q>+T`+,(&N:+[ZQ#`)E3N>/^
M.X*U*0X,:)HV#/L6;RTO7:K4/\C<2P8H"-K!EEQVE[/.+J_PGI,K$P%D5VZ6
M;'0)((NJ-%"@\6K"GM7M[*W=5G=`FPE:<XVSWHBU8'=_VD8*!-+4(BSEVK>.
MZ;`*GY(Y:=UA]VIWS+0HE;6#(OR]]\65HY!R_]FCLL=V%N?J:CBL5/<`[`HD
MQZD"PP*&KD+>G[-;$:&=>PTX$##/F45/J_<0ZF@99Q&BT?N^+3(+1*]0;NHH
MT.[<Y2)`H,%L@8_0+A_:<Q\$S&J*7'Q"611](L>,?Y"I#6QN;#L)!E>1F<(N
M6.\I]KV+WQ$[%\C<882`L0&HB66D`T*Y\/>!;JBM?23P&.0P-CK.2#!__'M<
M#SS7/1%`K"*:(^#\/A"`#PE,?D!+SX6F];RU79!U<..!FF1'@N/1H#<]T)^=
M1G@SWUE`%@($X0.P-H0[P>!#_HG3^5;0@-38ZFX\-,(+SS-"&WI@2CL:7@XS
MR#\9^<Y9F`-A!]PE0O\G\>.,:$3C<FH`IQ0L$06ZV4J(NO%$"`X"?L[;GPV6
M=X*>U>"$+-#ARZ+8PV5A)(@SD^)-;D##-]:0`/VJ`88<R10KQ@^*K6/!ZT+1
M-!J60)`F(Z0*/)<"1+HB=^-;I`!4-D&?P04`6%$C(\X%)$]RI'DBFM_T]"C)
M/G%1E+'Q'2J;(L9A^N`F4[%E`SD6248D@(_NF^+:$.<!R\UO)L<9`Q/\J!]?
M`O-G,2P"4OS'-S&>LH-@8P8"%```:"90!,+K1#Q<Y38[NJF%F`RG319I'G3]
M,I-"P!TZM49.X+%1#.Y\6S5+\+Y"3*5;(_A)'1F7&4#"$)\E."`_<1C(?^K_
M,PAY&^+FPD$!8:)3<-_,90I)0$W_`(``$"T!-6-*A>CEL056Y&<-8@I*:P*T
M:J8DH^["P\%4_I0*Y^M7DN*V.`@**Y1'1:%.;6#1$_3TID,(*<U*T+>N&?*8
M*6WE2C]&)X[Z0%C*+`*0L.C&.]VO+G"M2NPZ&E8-KD"KJ0J3%[\*NJC^*7$G
M:&@-6-F#<K&5*3R"ZD=-L$MCH8ZN?E4L1ED0U*V2@%5^^^(/N@C#A:*@I9=4
M`9T22@1N+I:*D?W`4XG0MAHPL'%UM=OW\NH*KHE@`Q4!8X["VE:?G:!?3BLL
M?/X5)3Q*E@6"K5,1U!1:U7ITLBF8K;(,I8)Y]?6T_]?QK0GB&471')8*\_GN
M12UH`YJN(+EFM>IS@]#5Z:J*!=9%:6K5I5V8:*$YQDN->(>@IN#Z%+L?:"T-
M]GM6+:;@JBH%\$AMYEZ+N8!5%*`7;SO;`M`F9T/I.&!S69A@?]5T<@=>KP_:
M:X(+Y-8'F)6O@AU;7_5V\@<')#`/!B`:Y>[0KX1+QURK)V(>D!A!FOU!BE?`
M6=0"=@7%[:X6$&!>%*@'P]<C6&/[,)T0QW9^0^8.7WO0H(GM=KX-8Y_DLH#?
M&7\($T$8P-B:&N6HSL5(2+(RF,6Z8A%D&<BS(<*/'S1A(WOVOS38\'8UFH!$
MN&`2:Y1Q;X^:W#+W@;D\OO_R?%D5+SR'<`A[CF"?W^G/IC5Y!&MNF@'4QS9(
MDH7%1YTA4Y+[/`33&;KQM?0`C:`UQCQKSFT^<@N2_*8@!&"-;#2`512`1->2
M]M4H$/`5_R6:NTA4FU*XAP9C38(,F#07TKT-KGFIZVIHH:J[#K5('!UF4T5.
M5X9U\4W*_#AJCT"@',EV5#8MU3\/T@:D-H-&C?&9OSXOQT;;,0EJ_`YVC\C$
M6\Z>*8U9A'4\Q;)%YK0WC?/I$A1@`<!V*``JCFS&IF]M]""L"`@N#8-#ZV]@
MS)L&3BK.RFIZVS?N]J&=:(0``.02_3@VMT7VYK4IFX$D9X;)?XIR($9,5WB%
M%%7_J&<VJP@A)E;1>0O6T`"J(('C/0A`5>IC%4%#QRH$(4!<Q^X/;&A]Z2BP
M0`76SO8?HH`";(^[99&N]KA7P.UVS+O>]\[WOOO][X`/O.`'3_C"&_[PB$^\
MXA?/^,8[_O&0C[SD)T_YREO^\IC/O.8WS_G.>_[SH`^]Z$>_B3`H$PQ(@.`9
M^+AZTKL>'U=/P1H"@/5<-"(!"]B4-2"8BA;V_O7`]R:Y(TJ#X>O=$\8GX5C_
M]7M803?XP-=&\J4?>#.F$<KVDCE3FD_%YT/?]=2/=/+M"%"X:*92VN<(]SGE
M_>^//OPN'C\$&;V,!Y)@]^U;O_S:[_[0PQ^V\M<^484T_Z2&>EX7%+X'<_W7
M>?_'4+$'>'ZU#."6=_H'1?RW@)[7@(GG5]J@+0:X:PT`$&?43BOP!I?Q)DL0
M"=P7@FA$@D!0=6?$3J3U@3P#$-03$PIP1@8P`??0>@Y(>S4T`3G(#SLH=8\4
M2X_`@U/W@"4(!S6D!%A@`%,P`K,'458@@OP``/DF.@J@%0D@A?.&41V8??:V
M7<$1&>=B$EM`#;\7`'3B6@>(:(10:)LP*PV0'\E'`&]X`W%0@>$7`$&'`%OH
M9,WT$,VE@=V73X4P<,6G$_OF`9A`0S2V#Z`0@0-&ABK01):``'/4"6SX$.6R
M!1.8(1EG#V.V)F066,66BG[8B/_BM@4<H$RO^&VSTX@#$QAJJ`6,:&,KTPP8
M<B0WY`\+H`^G,("]E#SI%RZXEP0-@!G&,1P$@$;K(0!I1!*IX(4+D`312%72
M(Q4`P(S.Z"3+8PWY08VDIHE.,FK:Z";"EDG2UQD"H(Y(8&K/J`*36`-=L([L
M$2>(R'XD$(UGM`P)D$:[.'P&Q![?F`0+T!^']1Y,9G%G48RG=0#U-QGXYW%.
M(G+P-#9<T4H)6$_WIQ6#B"()D&^30''HYUH80I$UD`DOX!!8H"W:H!7S]!9-
MXE^?9(IOX1"M9HNYU$+]Z%R\.`*=D0#QHQPM:0*5L%38LA<`=8(UD&\720(-
MQ8E'L`S_;>1\B^8!&DF%`NED;$1#O]9K9)A$R59_S54^L'6,*8`BSU,,!#8V
MPQ>4%FAET^>3/V,`-%0`^F!V>(D"UL<!Q88A4SD"6"``$&4-R5>!/X-1*))O
M6)"5^\259(B8*3`VI%4<,GE^+(`TU'$\BM89/4&7^`*4?UF0%H>/./65*'.:
M?+:)?%*8'^!'@R@_.%F:BU:;(K`>%N5'Q_8>]B<"UC"!K16`(Y`?FWE#WL1`
M;/%:*+`>;$6:D')40=F`S9E6?E06[R-CQE`?LKD;WE=<DW14U^@>F;0;B@9/
M;"F<-<!'UG*;;<DH#F%>#?42K<5TY%(#\B"=RW1:U8F7]UD$_^M!/2C(!!,0
MCO2!B=J&GT2IG(FHE=!#-MJFFQEUB?>W?+N8GB.P#,F97BR`!67F1[\B+CDY
ME!`:?W:9(?I9!$BC`)<25=V0$X794$W6,\&)FR<ZF<BX)M"FD&39FNGW`<O`
MH`VJ3]K0E2KP'KA8H#U:0G_)GXPY<JXII;P8I3!F`UWP+(ZY(H4IFW6H?59J
MI1>J:T#R#CNZ*`@T2,EY@")@+8'QB)Z07E!*G5,JE&6V&Z/H`^CH)+FG:9,E
MFF-J;UZJHP]:J(0*I")QIE_&IOVYICX0#8$1=)X0+'5:E^*7HL1GHD-@!73B
MDG<T60WE%EV*H8>Z?[T%7:/Z$&FTJO^LR@^*"IB!ID>.V@-N2@)L08VMFJO\
M`$ASZI]U^G]XRA10^28[D%I)B:@[FE8B$!TW.IVG):;(&JC*6JI*F:!FX8XT
M@*272370*GS69)J:2J4F=X%F,#82"5W'RI[=MI[DY:'.^I&HNGQ167.D*@+H
M.:)&ZJ`\`*(J2@/3F@+!2E[@>I>\Z$?_Z@,LB8H*=CRBNGS@.6/LBJ.&>HHF
M\+"Y<49=,:AMZB3*ZI9K:5[68)\1VY9GY(\?2J?A:J<?DZ[H1@-*JC0O(9O6
M0*$B`)Q*1)ZI)9LHXG6WJJ!G6:F*@ZWZ2E?,R;&[!IT8Z0&>=#P#BZE%"I\I
M2:2?ZE?%A3__7CJ3"84BBXFS*^:EAPE1***1&NNL::H"FKF6YE)A$7L\[CHW
M._4T0-LD37NI-<1&1_NC$C:&0Z(/CN:E#=61\8FW)CNQHH.A#?5,F8B5*8ED
MTZB;:EFB(\M2YC8:--09QH>U@8NR!$MNQ1"+]J@/]KDI/?.R;]&,6C%1@XHB
MJW0":E:/I_JZT$"JJMN5K>LD=S&V(I"P'E"3&:,/,0E;6N&B+]`DDKF61ED0
M#M&VRN<D;$(/<XNB%:N2*("4UMJ:_4:5RU"FC%"\ZEJ&^6D<"]``\U@<@`N[
MA+NXT]LTX8L$0M@TXUBOV(NE$Y`$,J$9K<@<Q:$`\XL$`%`KDBA1_PFI=3.A
M`#2$.!RPOUJ7'Z0+O0S\,<6!>^(;`"'8']1A#0@0P#:W#+T!#'J)OJ*SAR%C
M2V&:L_"[I_L@.[@[`J%A"<[0J`#8GXU`P(!&",89BEI``)#JM"_<6<V0;RN\
MO<7:"`C0IX4;I`%VADO&H"/<M?![Q,`FB%_JO6VYBI]QO\UQ`(7(!6Q:`(]X
MO>=%<L>;PW3;P&^!H#3AJ2C0`,V$9L(9!H>6!-'2O[OJ$L;CA'!DQT@&Q]4@
MQSB@A%6@Q\8S`5BHA9K@@ZBIPF(W@C"59HF<A8;F`P4@R/P@@R.`>GQ4A;+'
MA"DP`%4WA,(6AU5G=1BX@/PYRJ9\RKI2RB:HO,JL7#HIV\JP',L+`[2R7,NV
53,:WG,NZ?,B[W,N[K,J^7`0A```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
